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ABSTRACT 
Adult congenital heart disease (ACHD) patients have markedly depressed 
exercise capacity. This thesis examined (i) the prevalence of chronotropic 
incompetence, its relationship to symptoms and exercise capacity and its 
prognostic value In ACHD patients; (ii) investigated exercise capacity in 
patients with Eisenmenger syndrome and assessed survival prospects in this 
cohort as well as risk factors for mortality. In addition, clinical effects of 
Bosentan (a pulmonary vasodilator) were examined during longer-term 
follow-up. (ill) Mathematical modelling studies were employed to assess the 
impact of intracardiac shunting on oxygen delivery and tissue oxygenation 
potentially affecting exercise capacity, (iv) As pulmonary and systemic 
endothelial dysfunction are integral features of pulmonary arterial 
hypertension (and are related to exercise intolerance in this setting), this 
thesis examined the number and function of endothelial progenitor cells 
(EPC) in patients with idiopathic pulmonary hypertension and Eisenmenger 
syndrome. The main findings are: (i) chronotropic incompetence is prevalent 
in ACHD patients, relates to exercise intolerance and is an important 
prognostic marker across the spectrum of ACHD. However, chronotropic 
incompetence appears not to be causally related to exercise intolerance in 
many ACHD patients and artificially augmenting heart rate during exercise 
does not improve exercise capacity in many patients with a systemic right 
ventricle and a pre-existing pacemaker, (ii) Exercise intolerance is prevalent 
in patients with Eisenmenger syndrome and treatment with Bosentan 
improves objective exercise capacity in this cohort, (iii) This thesis shows 
how "unphysiologic" circulatory conditions and right-to-left shunt lesions limit 
exercise capacity. It also emphasises the limitations of physiologic concepts 
such as the concept of arterial oxygen delivery in ACHD patients with 
complex conditions, (iv) Finally, this thesis shows that patients with 
Eisenmenger syndrome have significantly lower EPC numbers and impaired 
EPC function and that the number of EPCs correlates directly with symptoms 
and objective exercise capacity. 
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Chapter I Introduction 
The work described in this thesis has been performed between February 
2005 and December 2007 at the Adult Congenital Heart Centre and Centre 
for Pulmonary Hypertension, Royal Brompton Hospital, London and the 
Section on Experimental Medicine and Toxicology, Imperial College London, 
Hammersmith Campus, London. 
1.1. Exercise Intolerance in Adult Patients with Congenital Heart 
Disease 
Adult congenital heart disease (ACHD) patients have markedly depressed 
exercise capacity (1-5). The presence and severity of symptoms are 
associated with a worse objective exercise capacity in these patients and 
relate to increased short-term mortality (6). Exercise intolerance in adults 
with congenital heart disease is multi-factorial as illustrated in Figure 1.1. In a 
previous study chronotropic response to exercise, pulmonary arterial 
hypertension and cyanosis were found to be the most important correlates of 
exercise intolerance (1). In addition to central haemodynamic factors the 
ability of the periphery to utilise oxygen may limit oxygen uptake in patients 
with congenital heart disease (7). 
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The physiologic components contributing to exercise capacity 
During exercise energy in the form of ATP is continuously produced in 
st<eletal muscles predominantly by aerobic metabolism. This requires 
adequate coupling of oxygen delivery to mitochondrial oxygen consumption. 
Other mechanisms such as anaerobic glycolysis and hydrolysis of 
phosphocreatine contribute to ATP production only to a minor extent if 
oxygen delivery is inadequate or at the beginning of exercise, respectively. 
As a consequence normal exercise capacity is dependent on the cardio-
respiratory chain comprised of ventilation, pulmonary perfusion and the 
cardiovascular system (including blood vessels and the microvasculature). 
Malfunction in any of these components (lungs, heart, blood, endothelial 
function) can limit exercise capacity. Congenital heart disease can affect all 
components of the cardio-respiratory chain, resulting in significant 
impairment of exercise capacity. 
Cardiac function during exercise plays a central role in the cardio-respiratory 
chain. As illustrated by the Pick principle peak oxygen consumption 
increases in proportion to increased cardiac output. Cardiac output, in turn, 
represents the product of stroke volume and heart rate. In patients with 
congenital heart disease numerous factors may limit stroke volume during 
exercise. Increased afterload to the subpulmonary ventricle may limit 
ventricular output during exercise in patients with pulmonary arterial 
hypertension. In addition, valvular dysfunction is prevalent in patients with 
congenital heart disease and may also limit stroke volume during exercise. In 
addition, various studies have demonstrated the importance of the interaction 
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between both ventricles. In patients with right ventricular volume overload 
(e.g. tetralogy of Fallot patients with severe pulmonary regurgitation) right 
ventricular enlargement and dysfunction impairs left ventricular function thus 
inducing biventricular dysfunction (i.e. ventriculo-ventricular interaction) (8). 
Shunt lesions such as atrial and ventricular septal defects may impose 
volume overload on the right and left ventricle, respectively (9). Furthermore, 
previous studies have demonstrated abnormal myocardial perfusion in 
subgroups of patients with congenital heart disease. Mauser et al. 
demonstrated perfusion abnormalities in patients with transposition of the 
great arteries after atrial switch operation (10). These perfusion abnormalities 
correlated to impaired ventricular function and to older patient age. 
Unfortunately stroke volume during exercise is particularly difficult to assess 
in patients with congenital heart disease due to abnormal anatomy and 
physiology. Several non-invasive techniques of assessing stroke volume 
during exercise (e.g. impedance cardiography, Doppler echocardiography 
and photoplethysmography) have been proposed but none of these have 
been validated in this cohort. Assessing stroke volume according to the Fick 
principle represents an invasive technique requiring measurement of central 
venous oxygen saturation (e.g. by placing a pulmonary catheter during 
exercise). As a consequence there are ethical concerns regarding the 
application of this technique for research purposes, only. Therefore, changes 
in stroke volume during exercise are largely unknown in adults with 
congenital heart disease. 
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Chronotropic incompetence 
While stroke volume increases predominantly at the beginning of exercise, 
further increase in cardiac output occurs mainly through increase in heart 
rate. Chronotropic incompetence represents an inappropriate increase in 
heart rate to meet the metabolic demands of exercise. Chronotropic 
incompetence is an established predictor of mortality in various 
cardiovascular cohorts as well as in healthy populations (11-14). An 
attenuated heart rate response to exercise has been reported across the 
spectrum of adult congenital heart disease (1,2). In a recent study peak heart 
rate was found to be the strongest physiologic determinant of exercise 
capacity in ACHD patients (1). Despite the importance of chronotropic 
incompetence no generally accepted definition of chronotropic incompetence 
is available. Currently used definitions are based on the heart rate response 
to exercise (15), comparative (16,17) and correlational (2,18) statistics. 
Cyanosis, pulmonary vascular disease and the Eisenmenger physiology 
Cyanosis and pulmonary hypertension significantly affect exercise capacity. 
Cyanosis reduces arterio-venous oxygen difference, while pulmonary arterial 
hypertension - representing an increased right ventricular afterload - limits 
stroke volume during exercise. Not surprisingly Eisenmenger patients, 
afflicted by a combination of both factors have a significantly impaired 
exercise tolerance as shown in previous studies (1,19). In addition to 
reducing arterio-venous oxygen difference, thereby limiting oxygen uptake, 
right-to-left shunting and cyanosis lead to an increased dead space 
ventilation (as venous blood is bypassing the lungs) inducing an exaggerated 
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increase in ventilation and a reduced ventilatory efficiency as suggested by 
high values of the VEA/CO2 slope in cyanotic patients (6). It has been argued 
that despite the apparent "inefficiency" of the ventilatory response to exercise 
in cyanotic patients leading to the early onset of dyspnoea and exercise 
limitation in these patients, the exaggerated ventilatory response is 
appropriate from a "chemical" point of view (7). In fact, it has been reported 
that arterial pH and PCO2 values are maintained at a normal or near normal 
value during exercise in patients with significant right-to-left shunting during 
exercise (20). 
Anaemia and secondary erythrocytosis 
As illustrated by the Pick equation (21) adequate haemoglobin concentration 
is closely linked to oxygen uptake and thus exercises capacity: 
VO2 = SV • HR • (Sat02art - Sat02ven) • K • Hb 
VO2 = oxygen uptake; SV = stroke volume ; HR = heart rate ; Sat02art = arterial oxygen 
saturation ; SatOgven = venous oxygen saturation; K = oxygen carrying capacity of blood 
(1.38 10"^ L O2 per gram haemoglobin); Hb = haemoglobin concentration . 
In fact, maximal oxygen uptake is directly proportional to haemoglobin 
concentration. As a consequence anaemia results in inadequate oxygen 
delivery to tissue during exercise, a premature shift to anaerobic metabolism 
during exercise and reduced exercise tolerance. The association between 
the presence of anaemia and reduced exercise capacity as well as impaired 
prognosis in patients with heart failure due to acquired heart disease is well 
established (22-25). Anaemia - as conventionally defined (26) - is 
occasionally encountered in non-cyanotic adult patients with congenital heart 
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disease. In contrast many cyanotic adult congenital heart disease patients 
have secondary erythrocytosis as reflected by elevated mean haemoglobin 
concentrations (27). Secondary erythrocytosis represents an adaptation to 
cyanosis and relates to arterial oxygen saturations thus helping to maintain 
oxygen carrying capacity of the blood (28). Patients who cannot maintain 
adequate haemoglobin concentrations due to frequent phlebotomies, iron 
deficiency or vitamin deficiency (29) have reduced exercise capacity and 
increased morbidity and mortality compared to patients with adequate 
haemoglobin levels (30,31). 
Endothelial dysfunction and Immune Inflammation 
The endothelium forms the interface between circulating blood and the rest 
of the vessel wall. In addition to forming a physical and metabolic barrier, the 
endothelium is an important endocrine organ (32). Numerous humoral 
factors released by the endothelium and influencing vascular tone have been 
identified. This area of research has received considerable clinical interest as 
some of these factors are now amenable to pharmacological therapy (33). 
These factors include nitric oxide, endothelin and prostacyclin (Figure 1.2). 
Nitric oxide (formeriy known as endothelium-derived relaxing factor, EDRF) 
is a potent vasodilator (34,35). Nitric oxide is produced by nitric oxide 
synthase (NOS) (36). Different isoforms of the enzyme have been identified 
(NOS l-lll). Nitric oxide synthase III (eNOS) is mainly expressed in 
endothelial cells, while NOS I and NOS III are found in neural tissue and 
inflammatory cells, respectively (32). Endothelial NOS is activated by 
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increased intracellular calcium concentrations through calcium-calmodulin 
interaction. Endothelial NOS generates nitric oxide from L-arginine with 
NADPH as a co-substrate and flavin adenine dinucleotide, flavin 
mononucleotide, and tetrahydrobiopterin as cofactors (37). Nitric oxide 
diffuses to neighbouring smooth muscle cells where it leads to increased 
intracellular levels of cyclic guanylate monophosphat (cGMP), thus inducing 
vasodilation and inhibiting cell proliferation (36). Cyclic GMP in turn is 
degraded by phosphodiesterases (PDEs). Pharmacological inhibition of 
PDEs, therefore, provides a way to augment intracellular cGMP levels. 
Sildenafil represents such a PDE-5 inhibitor currently employed for example 
in the treatment of pulmonary arterial hypertension (38). Asymmetric 
dimethylarginine (ADMA) is a metabolic by-product of continual protein 
methylation, a common mechanism of post-translational protein modification. 
It is closely related to L-arginine and represents a physiologic inhibitor of 
NOS. Increased levels of ADMA have been linked to various cardiovascular 
disorders (39). 
Endothelin was first described in 1988 and represents one of the most potent 
vasoconstrictors identified (40,41). Endothelin-1 (ET-1), the predominant 
form produced by endothelial cells, is synthesized as pre-pro-endothelin 
(pre-pro-ET-1) following translation from mRNA and is subsequently 
processed by furin-linke enzymes to big-ET-1. Big-ET-1 is cleaved by 
endothelin converting enzymes to ET-1 (42). Regulation of ET-1 production 
occurs mainly at the level of gene expression (43). Endothelin-1 activates 
endothelin A and B receptors on vascular smooth cells leading to calcium 
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release and activation of protein kinase C. Endothelin-1 is a potent 
vasoconstrictor with mitogenic, pro-fibrotic and pro-inflammatory properties 
(44). Endothelin receptor antagonists (ERAs) have been demonstrated to 
improve pulmonary haemodynamics in patients with pulmonary arterial 
hypertension (45). Their efficacy in improving 6 minute walk test distance as 
well as time to clinical worsening in patients with idiopathic pulmonary 
hypertension has been confirmed by several randomised controlled trials 
(46-52). Preliminary results also suggest that Bosentan may prolong survival 
in patients with advanced pulmonary arterial hypertension (53). As a 
consequence ERAs have become the mainstay of pulmonary arterial 
hypertension therapy. 
Reduced production of prostacyclin (PGI2) is an additional hallmark of 
endothelial dysfunction. Prostacyclin is formed by cyclo-oxygenase-1 and 
prostacyclin synthase from arachidonic acid liberated from membrane-bound 
lipids by phospholipase A2. Activation of prostacyclin receptors on smooth 
muscle cells induces stimulation of adenylate cyclase thus increasing 
intracellular cAMP levels, leading to vasodilation and antiproliferative effects. 
Different PGI2-analoga (Epoprostenol, lloprost, Treprostinil) have been 
developed and are commonly used in patients with pulmonary arterial 
hypertension. Intravenous Epoprostenol is generally regarded as first line 
treatment in patients with pulmonary arterial hypertension presenting in 
NYHA class IV (54). Intravenous prostacyclin administration is technically 
challenging and prolonged intravenous therapy is associated with frequent 
complications such as sepsis and line dislocation. Therefore, continuous i.v. 
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prostacyclin administration requires special expertise and extensive patient 
training. Treprostinil has been demonstrated to improve functional capacity 
and pulmonary haemodynamics and can be delivered subcutaneously. 
However, pain at the infusion site (in up to 85% of patients) prompting 
discontinuation of therapy in 8% of patients limit its use (55). Inhaled iloprost 
has been demonstrated to improve 6 minute walk test distance and NYHA 
class in patients with idiopathic pulmonary arterial hypertension, pulmonary 
arterial hypertension associated with connective tissue disease and 
thrombembolic pulmonary arterial hypertension and may represent an 
alternative to intravenous or subcutaneous prostacyclin analogues in 
selected patients (56). 
Endothelial dysfunction is ubiquitous in patients with heart failure and adults 
with congenital heart disease and relates to exercise Intolerance and 
symptoms (57-63). In addition, endothelial dysfunction is a predictor of 
outcome in patients with advanced heart failure (64,65). Furthermore, 
endothelial dysfunction has been found to improve after heart failure 
treatment (61,66). It has been postulated that endothelial dysfunction may 
have a detrimental effect on myocardial and skeletal muscle function (7). 
Endothelial dysfunction has been linked to reduced availability of vasoactive 
mediators (Figure 1.2), shear stress, oxidative stress, the presence of 
inflammation and reduced number of bone marrow derived endothelial 
progenitor cells (67-70) as illustrated in Figure 1.3. 
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This thesis aimed to elucidate some of the mechanisms limiting exercise 
tolerance in adult patients with congenital heart disease by performing 
retrospective and prospective clinical studies, employing mathematic 
modeling as well as using laboratory experiments to investigate endothelial 
progenitor cell numbers and function in patients with congenital heart 
disease. Patients with congenital heart disease represent a heterogeneous 
group and different mechanisms limit exercise capacity to a different degree 
in individual patients. As a consequence and for logistic reasons different 
sub-studies focused on different diagnostic groups such as patients with a 
systemic right ventricle, univentricular circulation or Eisenmenger syndrome. 
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1.2. Figures 
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Figure 1.1: Factors related to reduced peak oxygen consumption and 
exercise intolerance in patients with congenital heart disease. The Equation 
illustrates the Fick principle showing that oxygen uptake equals heart rate x 
stroke volume (SV) x the difference between arterial (CaOg) and venous 
(CVO2) oxygen content. 
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Figure 1.2: Components of the nitric oxide (NO), prostacyclin (PGh) and 
endothelin pathway regulating pulmonary vascular tone and pulmonary 
vascular remodelling. Nitric oxide is synthesized by endothelial NO-synthase 
(eNOS) from L-arginine. NO stimulates soluble guanylate cyclase (sGC) in 
smooth muscle cells resulting in increased production of cyclic GMP (cGMP) 
inducing vasodilation and antiproliferatory effects. Cyclic GMP in turn is 
degraded by phosphodiesterase 5 (PDE5). Prostacyclin (PGI2) is produced 
by cyclo-oxygenase-1 (COX-1) and PG^-synthase (PGI2S) from arachidonic 
acid (AA). Activation of prostacyclin receptors (PR) on smooth muscle cells 
induces stimulation of adenylate cyclase thus increasing intracellular cAMP 
levels leading to vasodilation and antiproliferative effects. Pre-pro-endothelin 
(pre-pro ET-1) is formed following translation from mRNA and is 
subsequently processed by furin-like enzymes to big-ET-1. Big-ET-1 is 
cleaved by endothelin converting enzymes (ECEs) to ET-1. ET-1 induces 
vasoconstriction and leads to smooth muscle cell proliferation via activation 
of ET-A and ET-B receptors with subsequent calcium release and activation 
of protein kinase C (PKC). Factors inducing vasodilation/antiproliferation are 
in green, those leading to vasoconstriction/proliferation in red. 
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Figure 1.3: Effect of various physiologic factors on endothelial function and 
endothelial progenitor cell (EPC) mobilisation from bone marrow, EPC 
differentiation and EPC function. 
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Chapter II Chronotropic Incompetence 
2.1. Background of the study 
Chronotropic incompetence — a blunted increase in heart rate during 
exercise — is an established predictor of mortality in various cardiovascular 
cohorts as well as in healthy populations (11-14). An attenuated heart rate 
response to exercise has been reported across the spectrum of adult 
congenital heart disease (ACHD)(1,2). In a recent study peak heart rate was 
found to be the strongest physiologic determinant of exercise capacity in 
ACHD patients (1). Despite the importance of chronotropic incompetence, its 
prevalence, association and causal relation to exercise intolerance are poorly 
understood. Furthermore little is known about the prognostic implications of 
chronotropic incompetence in ACHD patients. Similar to chronotropic 
incompetence, attenuation of heart rate recovery — the rate of decrease in 
heart rate after cessation of exercise — has been found to be associated 
with poor prognosis in patients being assessed for coronary artery disease 
(71). 
Despite the reported strong statistical association between peak heart rate 
and exercise capacity, attributing exercise limitation directly to chronotropic 
incompetence in an individual patient is difficult as no generally accepted 
definition or non-interventional method of assessing the functional impact of 
chronotropic incompetence exists. Currently used definitions are based on 
the heart rate response to exercise (15), comparative (16,17) and 
correlational (2,18) statistics. These methods, however, are based on large 
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numbers of patients, and cannot be directly applied to individual patients to 
determine whether a reduced peak heart rate during exercise is causally 
responsible for exercise intolerance. 
2.2. Association between chronotropic incompetence and exercise 
capacity 
Exercise testing with metabolic monitoring measures oxygen consumption 
(VO2) and heart rate simultaneously and has the potential to identify patients 
with an abnormal cardiovascular response to exertion. In healthy individuals, 
VO2 increases linearly in proportion to heart rate (72). Departure from 
linearity indicates the presence of a pathological condition, and provides 
information on the factors limiting exercise tolerance (72). Factors that impair 
cardiac output or arterio-venous oxygen difference (e.g. ventricular 
dysfunction or cyanosis) cause a disproportionately greater increase in heart 
rate than VO2. In contrast, factors that impair heart rate (e.g. chronotropic 
incompetence) lead to a disproportionately greater increase in VO2 than 
heart rate. The usefulness of such oxygen pulse kinetics (VO2 / heart rate) 
analyses in discriminating between underlying causes of exercise limitation 
in ACHD patients is unknown. 
This study tested the hypothesis that formal cardiopulmonary exercise 
testing with analysis of oxygen-pulse kinetics would identify individual 
patients in whom chronotropic incompetence was causally related to 
exercise intolerance. 
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2.2.1. Methods 
Study population 
All cardiopulmonary exercise tests performed in patients with a systemic right 
ventricle or univentricular circulation at the Adult Congenital Heart Disease 
Unit, Royal Brompton Hospital, London between January 2003 and May 
2004 were analysed. 
Patients with implanted pacemakers who were paced during exercise were 
excluded. Patients were referred for exercise testing as part of routine clinical 
follow-up. All patients underwent symptom limited exercise testing on a 
treadmill according to a modified Bruce protocol (73,74), with the addition of 
a "stage 0" in which the patient walked at a velocity of 1 mile/hour and a 
gradient of 5% for 3 minutes. Subjects were encouraged to exercise to 
exhaustion regardless of the maximal heart rate achieved. Ventilation, 
oxygen uptake and carbon dioxide production were measured continuously 
using a respiratory mass spectrometer (Amis 2000, Innovision, Odense, 
Denmark). Heart rate was measured continuously by electrocardiography 
and arterial blood pressure was assessed manually by sphygmomanometry. 
All patients gave informed consent prior to exercise testing. Anti-arrhythmic 
drug use was recorded at the time of exercise testing. Patients with resting 
oxygen saturations <90% were classified as cyanotic. In addition, 10 age-
matched healthy volunteers who underwent cardiopulmonary exercise 
testing using the same exercise protocol and measurement equipment as for 
the congenital heart disease patients were recruited. 
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Chronotropic incompetence 
Resting heart rates were recorded after a minimum of 30 seconds rest in a 
seated position. Peak heart rate was measured as the maximal heart rate 
achieved during exercise. Heart rate reserve was calculated as the 
difference between the peak and resting heart rate. The chronotropic index, 
(peak heart rate - resting heart rate) / (220 - age - resting heart rate) (13), is 
derived by applying the chronotropic metabolic relationship concept 
described by Wilkoff and colleagues to a symptom limited exercise test. This 
allows definition of the normal chronotropic response independently of age, 
resting heart rate and functional state (72). In a group of 410 healthy adults 
Wilkoff et al. (72) reported 95% limits of normality of chronotropic index to be 
0.8 - 1.3. Based on this finding, chronotropic incompetence was defined for 
the purpose of this study as failure to achieve a chronotropic index of 0.8 (i.e. 
falling below 97.5% of healthy adults). 
Oxygen uptal<e l<inetics 
In a subgroup of patients (n=43), who underwent exercise testing more 
recently, raw heart rate and gas exchange measurement data were available 
and were analysed prospectively using custom-written computer software 
(MatLab 6.5, Mathworks, Cambridge, UK). Oxygen pulse (02pu!se) was 
calculated as the instantaneous ratio of oxygen consumption (VOg) and heart 
rate (HR), representing the product between stroke volume and arterio-
venous oxygen difference (c(a-v)02) as shown in Equation 2.1 Therefore, 
any change in oxygen pulse is due to a change in one or both of these 
variables: 
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Oapulse = VO2 / heart rate = SV • C(a-v)02 Equation 2.1 
C(a-v)02 = oxygen content difference between arterial and mixed central venous blood. SV = 
stroke volume. 
In healthy individuals, oxygen consumption increases linearly in proportion to 
heart rate (72). Departure from linearity indicates the presence of a 
pathological condition and the nature of the departure provides information 
on the factors limiting exercise tolerance. Thus, linearity between heart rate 
and oxygen consumption was assessed using polynomial regression 
analysis. A quadratic equation (heart rate = a • V02^ + b • VO2 + c) was fitted 
to the second half of the exercise test. The quadratic coefficient a provides 
information about how far the regression line departs from linearity. Graphs 
are used to illustrate the relationship between heart rate and oxygen 
consumption during exercise in individual subjects. In addition, isopleths 
(lines of equal value) of oxygen pulse are superimposed to the graph to show 
changes in oxygen pulse during exercise. 
Statistical anaiysis 
All values are presented as mean ± standard deviation. Comparisons 
between groups were made using Student's t test, Mann-Whitney U test or 
Chi-squared test as appropriate. 
Influence variables were studied on univariate analysis. Significant 
parameters were subsequently included into a multivariate regression model 
in a stepwise forward procedure. For all analyses a P-value <0.05 was 
considered significant. Areas under curve (AUC) for sensitivity and specificity 
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were calculated using receiver-operating characteristics (ROC) to compare 
the predictive accuracy of different parameters. Statistical analyses were 
performed using MedCalc for Windows, version 7.5 (MedCalc Software, 
Mariakerke, Belgium). 
2.2.2. Results 
Patient characteristics 
Sixty-four adult congenital heart disease patients (mean age 28.1±11.3 
years, 37 male) with a systemic right ventricle or univentricular circulation 
were included. There were 12 patients with congenitally corrected 
transposition of the great arteries (ccTGA; 2 without associated lesions), 20 
patients after IVlustard-type atrial switch operation for transposition of the 
great arteries (TGA), and 32 patients with univentricular circulation (24 with 
atriopulmonary-Fontan, 4 with total cavopulmonary connection, 1 with 
classical Glenn, and 3 with bidirectional Glenn anastomosis). 
Patient baseline characteristics including parameters of chronotropic 
incompetence, peak oxygen consumption, presence of sinus rhythm and use 
of anti-arrhythmic drugs are listed in Table 2.1. There was no significant 
difference in age, gender, presence of cyanosis, NYHA functional class or 
anti-arrhythmic drug therapy between patients with and without chronotropic 
incompetence. Patients with chronotropic incompetence had lower values of 
chronotropic index, peak heart rate, heart rate reserve and percentage age 
predicted heart rate than those without chronotropic incompetence (Table 
2.1). 
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Exercise capacity and ventilatory efficiency 
Peak oxygen consumption was significantly reduced in patients compared 
with healthy control subjects (21.2±6.2 versus 39.4±3.4 ml/kg/min, P=0.04) 
as illustrated in Figure 2.1. Indeed, none of the patients included in the 
current study had normal peak oxygen consumption and only 5 patients had 
a peak oxygen consumption between 90 and 100% of the predicted value. 
Peak oxygen consumption in patients with ccTGA, univentricular circulation 
and Mustard operation was 20.0±7.1, 20.3+5.6, and 23.3±6.4 ml/kg/min, 
respectively. 
Ventilatory inefficiency (VE/VCO2 slope) was greater in the patients than the 
controls (41.6±17.3 versus 26.4±5.4, P=0.006) and was highest in those who 
were cyanotic (52.3±21.3). 
Relationship between chronotropic incompetence, symptoms and exercise 
capacity 
There was a non-significant trend towards a higher NYHA class in patients 
with chronotropic incompetence (49% NYHA class I, 38% NYHA class II, 
13% NYHA class III) compared with patients without chronotropic 
incompetence (56% NYHA class I, 44% NYHA class II, 0% NYHA class III, 
P=NS). While none of the patients with chronotropic competence were in 
NYHA class III, 5 patients with chronotropic incompetence reported severe 
exercise limitation. In contrast to subjective exercise tolerance, clear 
evidence of an association between impaired objective exercise capacity and 
chronotropic incompetence was found. 
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Patients with chronotropic incompetence had lower peak oxygen 
consumption (19.8 ± 5.5 versus 24.6 ± 6.8 ml/kg/min, P=0.005) as shown in 
Figure 2.1. Heart rate reserve (r=0.43, P<0.001) and peak heart rate (r=0.42, 
P<0.001) correlated with peak oxygen consumption. These results suggest 
that peak heart rate accounted for 18% (r^=18%) of the variation in peak 
oxygen consumption. On multivariate regression analysis, functional class 
(r=-0.34, %^=-3.1, P=0.003), peak heart rate (r=0.30, % =^2.9, P=0.006) and 
the presence of cyanosis (r=-0.27, %^=-2.6, P=0.01) were found to be 
independent predictors of peak oxygen consumption. 
Oxygen pulse and oxygen uptake - heart rate relationship 
Oxygen pulse at peak exercise was significantly lower in patients with ccTGA 
(10.3±3.5 ml/beat), Mustard operation (10.5±3.7 ml/beat) or univentricular 
circulation (8.4±2.4 ml/beat) compared with healthy individuals (15.3±3.5 
ml/beat, P<0.001 for each). In contrast, there was no significant difference in 
oxygen pulse between patients with chronotropic incompetence (9.2±2.9 
ml/beat) and those without (9.9+3.8 ml/beat, P=0.44). 
Oxygen pulse kinetics during exercise was assessed visually and by 
calculation of quadratic coefficients to determine the degree of non-linearity 
between VO2 and heart rate. On visual assessment 8 of 43 patients (19%) 
were found to have kinetics compatible with "functional" chronotropic 
incompetence (i.e. an inappropriate increase in heart rate compared with 
VO2) as illustrated in Figure 2.2D. In contrast, 13 of 43 patients (30%) had 
kinetics suggestive of exercise limitation due to an inappropriate oxygen 
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pulse, either due to an inappropriate stroke volume (e.g. due to ventricular 
failure) and/or arterio-venous oxygen difference (usually due to right-to-left 
shunting and arterial desaturation) as illustrated in Figure 2.2B and 2.2C. 
Visually, the remaining patients (51%) had a linear relationship between VO2 
and heart rate, thus, providing no further information on the aetiology of 
exercise limitation (Figure 2.2A). 
A good agreement between calculated quadratic coefficients and visual 
assessment of oxygen pulse kinetics was found (AUC on ROC analysis 0.96 
[95% confidence interval 0.84 - 0.99]). On ROC analysis a quadratic 
coefficient below -46 was identified as the optimal cut-off value 
discriminating between patients with and without oxygen pulse kinetics 
suggestive of chronotropic incompetence. A quadratic coefficient above 52 
ml/beat was associated with an oxygen pulse pattern suggestive of an 
inappropriate stroke volume and/or arterio-venous oxygen-content-difference 
as illustrated in Figure 2.3 (AUC 0.97 [95% CI 0.86-0.99]), sensitivity 100%, 
specificity 93%). 
Patients with a linear relationship between heart rate and peak VO2 had a 
significantly higher exercise capacity compared with those with a non linear 
response ("linear relationship" 24.6±6.1 versus 20.0±5.5 and 17.9+3.4 
ml/kg/min for inappropriate heart rate and inappropriate oxygen pulse, 
respectively, AN OVA P=0.003). A similar result was found when patients 
were stratified by a quadratic coefficient below -50, between -50 and 50, 
and above 50, respectively (ANOVA P=0.001). 
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The respiratory exchange ratio at peak exercise was not significantly 
different between patients with and without a linear oxygen pulse response 
and indeed was highest in patients with a linear response (1.07±0.09). This 
suggests that a linear response is not due to poor exertional effort by 
patients. 
2.3. Impact of optimized rate responsive pacing on exercise capacity 
In adults with a systemic right ventricle 
To further elucidate the association between heart rate response to exercise 
and peak oxygen consumption and to obtain further information on the 
factors limiting exercise tolerance in this setting 9 patients with systemic right 
ventricle (SRV) and pre-existing pacemakers were studied prospectively 
using Doppler echocardiography and treadmill exercise testing. This sub-
study investigated whether an artificial heart rate increase by reprogramming 
a pre-existing pacemaker during exercise leads to an improved exercise 
capacity. Furthermore, to assess the impact of heart rate increase on the 
physiology and filling of the systemic right ventricle, echocardiography was 
performed at rest and at higher heart rates. 
2.3.1. Methods 
This was a prospective exercise and echocardiographic study. From the 
institutional database of the Adult Congenital Heart Disease Unit, Royal 
Brompton Hospital, London all patients with a systemic right ventricle (n=180; 
congenitally corrected transposition of the great arteries (n=81), transposition 
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of the great arteries after Mustard (n=88) or Senning repair (n=11)) were 
identified. Of these, 19 had a permanent pacemaker implanted and were 
considered candidates for the study. Three patients could not be contacted 
as they had moved abroad. The remaining 16 patients were contacted and 
invited to take part in the study. Unfortunately, 5 refused to participate and 2 
were unable to perform an exercise test due to severe exercise limitation. 
Therefore, 9 patients with a systemic right ventricle could be examined. 
Control subjects matched for age without a history of heart disease were also 
studied with treadmill exercise testing. This sub-study was approved by the 
local ethics committee and all subjects gave written informed consent for this 
study. 
Cardiopulmonary Exercise Testing 
In patients with a systemic right ventricle two symptom limited 
cardiopulmonary exercise tests on a treadmill were performed on a single 
day. Recovery time between the tests was at least 3 hours. One test was 
carried out with the patient's pre-existing pacemaker settings. In those 
patients fitted with a rate responsive pacemaker, rate responsiveness was 
not switched off for the baseline test. The other test was carried out while the 
pacemaker was actively reprogrammed to simulate a normal heart rate 
response to exercise. Tests were performed in a randomized order with the 
patients blinded to the actual test protocol. Healthy volunteers underwent a 
single exercise test using to the same treadmill protocol. 
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All tests were performed according to a ramp protocol that uses a linear 
increase in walking speed coupled with a curvilinear increase in treadmill 
grade yielding a linear increase in work rate (75). 
The treadmill exercise protocol was individually adjusted for each patient by 
predicting peak work rate according to patient's height, age and gender. 
Peak work rate was calculated according to these equations (76): 
Males: 
WRpeak [Watts] = 1506 x Height(m)2.70 x Age(yrs)-0.46 / 6.12 Equation 2.2 
Females: 
WRpeak [Watts] = 969 x Height(m)2.80 x Age(yrs)-0.43 / 6.12 Equation 2.3 
WRpeak= predicted peak work rate in Watts 
Subsequently, the treadmill velocity range was determined. Starting speed 
was set at 0.5 mph; maximum speed after 10 minutes of exercise was set at 
3.5-4 mph to allow the subject to walk comfortably during the entire test 
period and to avoid change in gait pattern leading to a steeper rise of 
metabolic rate per calculated work rate than established over a slower speed 
range. Changes In work rate and speed were spread linearly over 20 stages 
to reach the target work rate after 10 minutes of exercise. 
The inclination of the treadmill was calculated based on the subjects body 
weight, the desired initial and 10 minute speeds, the initial grade and the 
predicted 10 minute work rate according to the formula provided by Porszasz 
(75): 
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WRpeak= predicted peak work rate in Watts, m=body mass in kilograms, g=gravitational 
acceleration (9.81 m/s^), Vo and Vmax=desired initial and final treadmill speeds, gradeO=initial 
treadmill grade 
TIlis treadmill ramp protocol was chosen as it provides a near linear increase 
of work rate and allows prediction of a normal heart rate response as heart 
rate relates in a predictable linear fashion to work rate. The pacemaker was 
programmed to simulate a normal heart rate response according to the data 
provided by Kindermann et al. based on the relationship between work rate 
and heart rate response (77). 
All subjects were encouraged to exercise to exhaustion regardless of the 
maximal heart rate achieved. Ventilation, oxygen uptake and carbon dioxide 
production were measured continuously using a respiratory mass 
spectrometer (Amis 2000, Innovision, Odense, Denmark). Heart rate was 
recorded by continuous electrocardiography and arterial blood pressure was 
recorded manually by sphygmomanometer. 
Resting heart rate measured after 30 seconds in a seated position and 
maximal heart rate achieved during exercise testing were recorded. Exercise 
duration, peak oxygen consumption, ventilatory response to exercise 
expressed as ventilation per unit of carbon dioxide production (VEA/CO2 
slope), arterial oxygen saturation at rest and at maximum exercise where 
also recorded. 
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Echocardiography 
Transthoracic echocardiography was performed in all patients with SRV 
using a standardized transthoracic approach with a Philips Sonos 7500 
echocardiograph interfaced with a multifrequency MHz transducer. 
Transtricuspid (systemic atrioventricular valve) pulsed wave Doppler 
recordings were obtained from the apical 4-chamber view and aortic pulsed 
wave Doppler recordings were acquired with anterior angulation of the 
transducer with the sample volume at the tips of the respective valve leaflets 
(78). All recordings were made simultaneously with ECG and 
phonocardiogram and were stored digitally for offline analysis using Medcon 
software (Medcon Telemedicine Technology, Whippany, NJ). 
The timing of the systemic right ventricular cardiac cycle was measured from 
aortic and tricuspid valve pulsed wave Doppler recordings at resting heart 
rate (68±8 bpm) as well as 106±10 bpm and 140±9 bpm. Systemic 
ventricular ejection time (ET) was measured as the interval from the onset to 
the end of forward flow across the aortic valve. Filling time (FT) of the 
systemic ventricle was measured from the transtricuspid flow recording as 
the interval from the onset of the E wave to the end of the A wave. Time 
intervals were multiplied by heart rate and expressed as seconds per minute 
as these values are independent of the heart rate. Total isovolumic time (t-
IVT), the time of the cardiac cycle were the ventricle is neither filling nor 
ejecting, also expressed in seconds per minute was calculated as: 60-(t-ET + 
t-FT), where t-ET and t-FT represent total ejection and filling time expressed 
in seconds per minute. The aortic velocity time integral (VTI) was calculated 
from the aortic valve Doppler tracings. 
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To assess ventricular long axis function M-mode and tissue Doppler 
recordings of the lateral wall of the systemic (right) ventricle, the ventricular 
septum, and the free wall of the subpulmonary (left) ventricle were obtained 
from the apical four chamber view with the sample volume positioned at the 
right and septal angles of the mitral valve ring and the left angle of the 
tricuspid valve ring as described previously (78,79). The maximal diastolic 
inlet width of the systemic right ventricle has been reported a good correlate 
of end diastolic ventricular volume from cardiovascular magnetic resonance 
imaging and was, therefore, obtained from the apical four chamber view to 
quantify systemic right ventricular size (79). A qualitative, subjective 
assessment of systemic right ventricular size and function from multiview 2-
dimensional echocardiography was also employed as previously described 
(80). Systolic ventricular function was graded as normal, mildly, moderately, 
or severely impaired. Ventricular size was graded similarly as normal, mildly, 
moderately, or severely enlarged. A corresponding numerical grading from 1 
to 4 was for calculations. 
Statistical Analysis 
For all measured variables, values are expressed as mean ± SD or median 
and range. Comparisons between groups were made using Mann-Whitney U 
test (unpaired samples), Wilcoxon test (paired samples) and Chi-squared 
test as appropriate. Statistical analysis was performed using MedCalc for 
Windows, version 9.2.0.0 (MedCalc Software, Mariakerke, Belgium). 
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2.3.2. Results 
Patient characteristics 
There was no significant difference between patients (n=9) and controls 
(n=8) regarding age (36.4±9.4 versus 32.7±5.0, P=0.37) and gender 
distribution (P =0.74). Individual patients' characteristics are outlined in Table 
2.2. 
Exercise capacity and heart rate response to exercise 
Complete exercise data with two tests at different pacemaker settings could 
be obtained in 7 of 9 patients. One patient refused repeat testing after an 
uneventful first test without explanation. A second patient developed 
symptomatic atrial tachycardia after two minutes of the initial test and 
therefore no repeat testing was performed. 
Peak heart rate, exercise duration and peak oxygen consumption were 
significantly reduced and VEA/CO2 slope was abnormally elevated in 
patients with SRV compared to controls (Table 2.3). 
Pacemaker reprogramming resulted in an increase of peak heart during 
exercise from 135±32 to 149±22 beats per minute. However, due to large 
inter-individual variability and the development of atrial tachyarrhythmia 
during the exercise test with the pre-existing pacemaker settings in one 
patient this increase was not statistically significant. Overall, active 
reprogramming did not result in an increase of peak VO2 (12.6+6.8 versus 
12.4±4.9 ml/kg/min, P=0.44). In fact, in none of the patients a clinically 
relevant improvement of peak VO2 was achieved with active pacemaker 
reprogramming (Figure 2.4). Interestingly, even in the patient with the largest 
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improvement of heart rate response (82 to 162 bpm), peak VO2 decreased 
from 10.7 to 8.9 ml/kg/min. While in all control subjects VO2 Increased 
linearly with heart rate, a markedly non-linear VO2 to heart relationship was 
observed in 6 of 8 patients as illustrated in Figure 2.5. 
Physiology of systemic right ventricular cardiac cycle and heart rate 
The timing of the systemic right ventricular cardiac cycle was markedly 
altered by increase in heart as a result of pacemaker reprogramming. There 
was a significant increase in t-IVT accompanied by a marked reduction in t-
FT and aortic VTI with increasing heart rate (Figure 2.6 and 2.7). In fact, 
these two parameters decreased in all patients studied. In addition, t-ET 
increased significantly from baseline to maximum heart rate (18.3±2.3 versus 
21.9±2.3, P=0.008 at 68±8 and 140±9 bpm, respectively) whereas peak 
aortic velocity remained unchanged (82.7±16.1 versus 76.8±16.1 cm/s, 
P=0.55 at 68±8 and 140±9 bpm, respectively). 
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2.4. Prognostic value of chronotropic incompetence in ACHD 
patients 
The aims of this study were to evaluate the prevalence of an abnormal heart 
rate response to exercise (chronotropic incompetence) in ACHD patients, to 
assess the relationship between heart rate response and exercise capacity, 
and to evaluate whether chronotropic incompetence is a prognostic marker in 
ACHD patients after accounting for exercise capacity and use of anti-
arrhythmic medication. 
2.4.1. IVIethods 
Study population 
Data from all cardiopulmonary exercise tests performed in ACHD patients at 
the Adult Congenital Heart Unit, Royal Brompton Hospital London between 
February 1999 and April 2005 were analysed retrospectively. Patients were 
referred for exercise testing as part of clinical follow-up for ACHD patients. 
This study was approved by the local ethics committee. Almost all patients 
underwent only one test during the study period. Any repeat test was not 
included in the analysis. A main diagnosis was determined for every patient 
from the hospital records. Patients with multiple, complex cardiac lesions 
substantially affecting haemodynamic function were classified as complex 
anatomy (comprising mainly patients with single ventricle physiology). The 
New York Heart Association (NYHA) functional class was determined by 
physician assessment of patients' self-reported symptoms before the date of 
the exercise test. Anti arrhythmic drug use was recorded at the time of 
exercise testing. 
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Cardiopulmonary exercise testing 
Cardiopulmonary exercise testing was performed on a treadmill according to 
a modified Bruce protocol (73,74) with the addition of a "stage 0" in which the 
patient walks at a velocity of 1 mile/hour and a gradient of 5% for 3 minutes. 
All subjects were encouraged to exercise to exhaustion regardless of the 
maximal heart rate achieved. Ventilation, oxygen uptake and carbon dioxide 
production were measured continuously using a respiratory mass 
spectrometer (Amis 2000, Innovision, Odense, Denmark) as described 
previously (81). Heart rate was assessed by continuous electrocardiography 
and arterial blood pressure was recorded manually by sphygmomanometry. 
Resting heart rate was measured after at least 30 seconds in a seated 
position and peak heart rate was defined as the maximal heart rate achieved 
during exercise. Predicted maximum heart rate was estimated according to 
the formula 220-age (82), and percentage of maximum age-predicted heart 
rate was calculated as the ratio between peak heart rate and age-predicted 
maximum heart rate 220-age. 
Calculation of heart rate reserve 
Heart rate reserve was calculated as the difference between peak and 
resting heart rate. The chronotropic index, (peak heart rate - resting heart 
rate) / (220 - age - resting heart rate), is derived by applying the 
chronotropic metabolic relationship concept introduced by Wilkoff to a 
symptom limited exercise test as described previously (13,72). This allows 
definition of the normal chronotropic response independently of age, resting 
heart rate and functional state (72). In a group of 410 healthy adults Wilkoff 
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et al. reported 95% limits of normality of chronotropic index to be 0.8 - 1.3. 
Based on this finding, we defined chronotropic incompetence as failure to 
achieve a chronotropic index of 0.8 (i.e. falling below 97.5% of healthy 
adults) (72). 
Calculation of heart rate recovery 
Heart rate was also recorded 1,2,3 and 5 minutes after the cessation of 
exercise and heart rate recovery calculated as the difference between peak 
heart rate and the heart rate at these recovery time points. In addition, the 
relative decrement in heart rate was calculated as heart rate recovery divided 
by the heart rate at peak exercise. 
Follow-up 
Follow-up was complete for all patients. Survival status and time to death 
was assessed through the health service computer system, which is linked to 
a national database held by the Office of National Statistics. The study was 
planned to use all-cause mortality as the end-point in order to eliminate any 
possibility of bias arising from incorrect classification of cause of death. 
Statistical analysis 
All values are presented as mean ± standard deviation. Comparisons 
between groups were made using Student's t test, Mann-Whitney U test or 
Chi-squared test as appropriate. Variables were assessed on univariate 
analysis. Significant parameters were subsequently included into a 
multivariate regression model in a stepwise forward procedure. Univariate 
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Cox proportional-hazards analysis was used to assess the association 
between variables and the endpoint of all cause mortality. Parameters 
significantly predicting prognosis in univariate analysis were subsequently 
tested in a multivariate Cox proportional-hazards analysis by the stepwise 
forward method to assess the independent effect of these variables. Areas 
under curve (AUC) for sensitivity and specificity were calculated using 
receiver-operating characteristics (ROC) analysis to compare prognostic 
accuracy of different parameters. Statistical analyses were performed using 
the StatView 5.0 package (Abacus Concepts, Berkeley, CA, U.S.A.). 
2.4.2. Results 
Patient characteristics 
Characteristics of the 727 consecutive ACHD patients (mean age 33 ±13 
years, 52% male) included in this analysis are presented in Tables 2.4 and 
2.5. Patients with chronotropic incompetence were more likely to be cyanotic, 
female or treated with anti-arrhythmic drugs. In addition, by definition, such 
patients had lower values of peak heart rate and heart rate reserve as shown 
in Table 2.4. 
Prevalence of chronotropic incompetence 
Chronotropic incompetence was present in 62% of the patients. The 
prevalence was highest in patients after Fontan palliation (84%) and in 
patients with Eisenmenger physiology (90%), while it was lowest in patients 
with repaired tetralogy of Fallot (52%), repaired ventricular septal defect 
(52%) and isolated valvar disease (47%) as shown in Table 2.5. On
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considering only those patients who reached anaerobic threshold (i.e. those 
with a respiratory quotient above 1.0) the frequency of chronotropic 
incompetence was found to be 54% overall. Once again it was most frequent 
in the Eisenmenger patients (96%) and least frequent in patients with 
repaired ventricular septal defects (35%). 
Relationship to symptoms and exercise capacity 
Patients with chronotropic incompetence were more likely to be in a higher 
NYHA class (34% NYHA class I, 47% NYHA class II, 19% NYHA class III) 
compared to the other patients (64% NYHA class I, 30% NYHA class II, 6% 
NYHA class III, P<0.0001). Patients with chronotropic incompetence also 
had lower peak oxygen consumption (20.4±8.2 vs. 28.0±9.9 ml/kg/min, 
P<0.0001), and shorter exercise duration (541 ±196 vs. 732±196 seconds, 
P<0.0001). In addition, heart rate reserve (r=0.53, P<0.0001) and peak heart 
rate (r=0.49, P<0.0001) correlated with peak oxygen consumption. 
Prognostic value of parameters of chronotropic incompetence 
During a median follow-up of 851 days after cardiopulmonary exercise 
testing (range 60 - 2254 days) 38 patients died. Patients who died had the 
following diagnoses: Fontan physiology (n=7), complex anatomy (n=10), 
congenitally corrected transposition of the great arteries (n=2), atrial switch 
procedure for transposition of the great arteries (n=1), tetralogy of Fallot 
(n=5), isolated valvar disease (n=2), single ventricle physiology (n=1), aortic 
coarctation (n=1), Ebstein anomaly (n=3), repaired atrial (n=1) and atrio-
ventricular (n=2) septal defects and others (n=2). 
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On univariate analysis heart rate reserve (%2 = 26.1), chronotropic index (%2 
= 26.9), peak heart rate (%2 = 20.9), percentage predicted heart rate (%2 = 
21.0), use of anti-arrhythmic drug therapy (%2 = 24.0), peak oxygen 
consumption (%2 = 19.3) and NYHA class (%2 = 17.2) were significant 
predictors of survival. In addition amiodarone (%2 = 30.1) or digoxin (%2 = 6.0) 
use was related to survival as shown in Table 2.6. Age, gender, cyanosis 
and treatment with sotalol, beta-blocker, calcium-antagonist, class I anti-
arrhythmic drugs or ACE-inhibitors were not related to survival. 
Measures of chronotropic response correlated strongly with each other (r-
value between 0.81 and 0.96, P<0.001 for each). Therefore, for multivariate 
analysis the parameter with the highest predictive value on univariate Cox 
proportional-hazard analysis and the greatest area under curve on ROC 
analysis was chosen. In both analyses heart rate reserve (%2 = 26.1, AUC = 
0.74) and chronotropic index (%2 = 26.9, AUC = 0.74) were superior to peak 
heart rate (%2 = 20.9, AUC = 0.72) and percentage age predicted peak heart 
rate (%2 = 21.0, AUC = 0.72) in predicting prognosis. As a consequence 
heart rate reserve, representing a much simpler parameter than chronotropic 
index was used in subsequent analyses. 
To investigate the predictive power of heart rate reserve independently of 
other prognostic variables, bivariate analyses were performed. Heart rate 
reserve predicted mortality independently of peak oxygen consumption, anti-
arrhythmic therapy and NYHA class (Table 2.7). On multivariate analysis, 
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heart rate reserve, NYHA class and therapy with anti-arrhythmic drugs jointly 
predicted mortality, independent of peak oxygen consumption, as shown in 
Table 2.7. These results remained unchanged when patients who did not 
reach the anaerobic threshold during exercise (i.e. those with a respiratory 
quotient below 1.0) were excluded from the analyses. 
Prognostic value of heart rate reserve in individual diagnostic groups 
Heart rate reserve predicted mortality in patients after Fontan palliation (%2 = 
7.5, hazard ration 1.48 per 10 bpm; 95% CI 1.10-2.16, P<0.05), complex 
anatomy (%2 = 3.8, hazard ratio=1.21 per 10 bpm; 95% C11.10-1.48, 
P<0.05) and repaired tetralogy of Fallot (%2 = 6.3, hazard ratio=1.48 per 10 
bpm; 95% CI 1.10-2.16, P<0.05) on univariate analysis. No significant 
association between low heart rate reserve and mortality was found in 
patients with simple lesions, systemic right ventricles or Ebstein anomaly of 
the tricuspid valve. 
Comparative and combined prognostic value of heart rate reserve and peak 
oxygen consumption 
Heart rate reserve was at least as good as peak oxygen consumption in 
predicting mortality, both on univariate Cox analysis (%2 = 26.1 vs. 19.3) and 
on ROC analysis (AUC 0.74 vs. 0.68). Combining these two variables was 
also helpful: patients with both heart rate reserve and peak oxygen 
consumption within the lowest quartile had the worst prognosis, patients with 
only one in the lowest quartile had an intermediate prognosis, and those with 
neither in the lowest quartile had the best prognosis (P<0.0001). Kaplan-
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Meier-Estimates of death from any cause among adult congenital heart 
disease patients with stratified by quartiles of heart rate reserve are shown in 
Figure 2.8. 
Prognostic value of heart rate recovery 
Data on heart rate recovery was available in 505 patients (those patients 
who underwent exercise testing after March 2001). Of these, 16 patients died 
during follow-up. Heart rate recovery at 1,2, 3 and 5 minutes was 
significantly lower in patients who died compared to surviving patients 
(P<0.05 for each) as was heart rate recovery expressed as percentage of 
peak heart rate (Figure 1.9). Heart rate recovery at 1,2, 3 and 5 minutes 
after exercise was significantly related to mortality on univariate Cox 
proportional hazards analysis (P<0.05 for each). After adjustment for anti-
arrhythmic drug therapy heart rate recovery at 1,2, 3 and 5 minutes after 
exercise remained independently predictive of survival in bivariate Cox 
analysis (P<0.05 for each). 
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2.5. Tables 
Characteristic All patients Failed * Reached * P Value 
(n=64) (n=46) (n=18) 
Age (years) 28 ±11 27 ± 8 30± 14 0.26 
Gender (%male) 58% 54% 67% 0.41 
NYHA 1/11/III 51%/40%/9% 49%/ 38%/13% 56%/44%/ 0% 0.29 
Cyanosis 22% 26% 11% 0.31 
Sinus rhythm 90% 82% 94% 0.31 
Class l-IV anti-arrhythmic drugs ^ 35% 39% 29% 0.75 
Anti-arrhythmic drugs incl. digoxin 40% 39% 41% 0.89 
Digoxin 4% 0% 12% 0.12 
Amiodarone 23% 26% 18% 0.72 
Sotalol 10% 13% 6% 0.64 
Betablocker 4% 3% 6% 0.75 
Heart rate reserve (bpm) 71 ±27 61 ±23 97 + 19 <0.001 
Chronotropic index 0.66 ± 0.32 0.52 ±0.19 1.02 ±0.33 <0.001 
Peak VO2 (ml/kg/min) 21.2 + 6.2 19.8 ±5.5 24.6 ± 6.8 0,005 
% age-predicted heart rate 0.79 ±0.18 0.71 ±0.12 0.99 ±0.13 <0.001 
Peak pulse (bpm) 151 ±32 137 ±24 185 ±22 <0.001 
Resting pulse (bpm) 80 ±14 77 ±12 89± 15 0.001 
P-values (unpaired t-test or x / Fisher's exact test) for comparison between patients 
achieving and patients failing to reach a chronotropic index of at least 0.8. NYHA = New 
Yort< Heart Association class, bpm = beats per minute. Peak VO2 = peak oxygen 
consumption. 
^ Classification of anti-arrhythmic drugs according to the Vaughan Williams classification. 
Table 2.1: Selected baseline characteristics according to the ability to reach 
a chronotropic index of at least 0.8*. Plus-minus values are mean ± standard 
deviation 
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Sex Age Diagnosis PM Indication PIVI Mode 
at Baseline UTR Notes 
(M/F) (yrs) (bpm) 
M 35 TGA, Mustard sympt. Bradycardia DDDR 140 
M 35 TGA, Mustard sympt. Bradycardia W l -
F 27 TGA, Mustard sympt. Bradycardia DDIR 120 
M 50 ccTGA sympt. Bradycardia DDDR 150 AT 2nd test 
F 50 ccTGA complete heart block W I R 150 AT 1 st test, no 2nd test 
F 39 TGA, Mustard sympt. Bradycardia DDDR 120 
M 39 TGA, Mustard complete heart block DDDR 145 
F 23 TGA, Mustard complete heart block DDDR 130 refused 2nd test 
M 30 TGA, Mustard complete heart block DDDR 140 
Diagnosis; TGA, transposition of tlie great arteries (=D-TGA); ccTGA, congenitaiiy corrected 
TGA. PM, pacemaker; bpm, beats per minute; AT, atrial tachycardia. UTR = upper tracking 
rate 
Table 2.2: Baseline characteristics 
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Patients with 
SRV Controls 
Exercise Duration, sec 494 ± 179 758 ± 125 0.005 
Peak HR, bpm 135 ± 32 186 ± 11 0.0006 
Peak VO2, ml/kg/min 12.6 ± 6.8 31.4 ± 6.6 0.0006 
VEA/CO2 slope 57.4 ± 123 36.6 ± 7.7 0.002 
Data from patients with systemic right ventricle (SRV) obtained from tests with pre-
existing pacemaker settings; bpm, beats per minute; HR, heart rate; VO2, oxygen 
consumption; VE, ventilation; VCO2, carbon dioxide production. 
Table 2.3: Parameters of cardiopulmonary exercise testing in SRV patients 
and control subjects. 
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Characteristic All patients 
(n=727) 
Failed * 
(n=453) 
Reached * 
(n=274) 
P Value 
Age (years) 33 + 13 33± 13 33± 13 0.87 
Gender (%male) 52 47 61 0.001 
Deaths 38 34 4 0.0004 
NYHA 1 / II / III (%) 4 5 / 4 0 / 1 5 3 4 / 4 7 / 1 9 6 4 / 3 0 / 6 <0.0001 
Cyanosis (%) 17 24 5 <0.0001 
Sinus rhythm (%) 96 96 97 0.34 
Class l-IV ^ anti-arrhythmic drugs 28 39 10 <0.0001 
(%) 
Anti-arrhythmic drugs incl. digoxin 26 37 7 <0.0001 
(%) 
Digoxin (%) 5 6 4 0.18 
Amiodarone (%) 13 19 3 <0.0001 
Sotalol (%) 4 5 2 0.02 
ACE inhibitors (%) 19 21 16 0.14 
Heart rate reserve (bpm) 71 ± 2 9 57 ±24 95± 18 <0.0001 
Chronotropic index 0.70 ± 0.28 0.54 ± 0.20 0.96 ± 0.20 <0.0001 
Peak VO2 (ml/kg/min) 23.3 ±9.6 20.4 ± 8.2 28.0 ±9.9 <0.0001 
Percentage age-predicted heart 83± 16 7 4 + 1 3 97 + 8 <0.0001 
rate 
Peak pulse (bpm) 154 ±30 138 ±26 181 ± 14 <0.0001 
Resting pulse (bpm) 83 ± 1 4 82± 16 85± 15 0.004 
P-values (t-test or Mann-Whitney U-test) for comparison between patients achieving and 
patients failing to reach a chronotropic index of at least 80%. ACE = angiotensin converting 
enzyme. NYHA = New Yorl< Heart Association class, bpm = beats per minute. Peak VO2 = 
peak oxygen consumption. 
* Plus-minus values are mean ± standard deviation 
^ Classification of anti-arrhythmic drugs according to Vaughan Williams. 
Table 2.4: Selected baseline characteristics according to the ability to reach 
a chronotropic index of at least 0.8 * 
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Low CI HRR Peak Pulse peak VO2 Sinus AAD treatment 
(bpm) (bpm) (ml/kg/min) rhythm 
ASD (n=42) 60% 69+30 154+34 21 •6+7-9 89% 32% 
ccTGA (n=25) 68% 70+33 151+38 21 8+9 6 95% 43% 
CoA (n=23) 59% 73+24 156+27 28 9+7 9 95% 30% 
Complex (n=75) 81% 56±28 138+32 202+7 7 88% 35% 
Ebstein (n=32) 53% 77+28 158+31 21 •5+5-2 90% 35% 
Eisenmenger (n=53) 90% 51 ±23 136+24 12-8±5-7 100% 40% 
Fontan (n=58) 84% 59±27 140+33 20 9+6-1 96% 53% 
Mustard (n=56) 58% 77+26 160+28 25 8±6 9 94% 29% 
TOP (n=228) 52% 80+26 162+26 25-7+8-4 98% 19% 
Valvar (n=78) 47% 76+31 159+29 26 9±12 8 97% 17% 
VSD (n=25) 52% 70+27 157+26 22-2+7-1 100% 13% 
ASD = atrial septal defect, ccTGA = congenitally corrected transposition of the great arteries 
(TGA=L-TGA), CoA = aortic coarctation. Complex = complex anatomy including mostly 
single ventricle physiology (excluding Fontan type patients), Mustard = patients after 
Mustard type atrial switch operation for TGA, TOP = tetralogy of Fallot, VSD = ventricular 
septal defect. 
bpm = beats per minute. Low CI = percentage of patients with a low chronotropic index 
(<0'8), HRR = heart rate reserve (beats per minute), peak pulse (beats per minute), peak 
VO2 = peak oxygen consumption (ml/kg/min). Sinus rhythm = percentage of patients in sinus 
rhythm at the time of the exercise testing, AAD treatment = percentage of patients treated 
with at least one anti-arrhythmic drug (including type l-IV or digoxin). 
* Plus-minus values are mean ± standard deviation 
Table 2.5: Distribution of parameters of chronotropic incompetence, peak 
oxygen consumption, presence of sinus rhythm and use of antiarrhythmic 
drugs by underlying anatomy 
63 
Variable Hazard Ratio * 
(95% confidence interval) 
P value 
Parameters of chronotropic incompetence 
Heart rate reserve (bpm) 1.03 (1.02-1.04) <0.0001 
Chronotropic index 1.03 (1.02-1.04) <0.0001 
Peak heart rate (bpm) 1.02 (1.01 -1 .03 ) <0.0001 
Percentage predicted peak heart 1.04 (1.02-1.05) <0.0001 
rate 
Heart rate recovery 1 minute 1.04 (1.01 -1 .06 ) 0.002 
(bpm) 
Heart rate recovery 2 minutes 1.04 (1.02-1.06) 0.0002 
(bpm) 
Heart rate recovery 3 minutes 1.03 (1.01 -1 .04 ) 0.001 
(bpm) 
Heart rate recovery 5 minutes 1.03 (1.01 -1 .04 ) 0.002 
(bpm) 
Other univariate predictors 
Peak VO2 (ml/kg/min) 0.90 (0.86-0.94) <0.0001 
NYHA class 2.7 (1 .7-4 .4) <0.0001 
Anti-arrhythmic therapy (excl. 5.4 (2.7-11.0) <0.0001 
digoxin) 
Anti-arrhythmic therapy (incl. 3.0 (6.3-13.2) <0.0001 
digoxin) 
Amiodarone therapy 3.4 (6.6-12.9) <0.0001 
Digoxin therapy 3.3 (1 .3-8 .4) 0.01 
NYHA class = New York Heart Association class, peak VO2 = peak oxygen consumption 
(ml/kg/min). 
* Hazard ratios for heart rate reserve and peak oxygen consumption are per beat per minute 
and one ml/kg/min, respectively. 
Table 2.6: Univariate predictors of mortality 
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Variable Hazard Ratio * 
(95% confidence interval) 
P value Value 
Bivariate Analyses 
Heart rate reserve (bpm) 
Anti-arrhythmic therapy (incl. digoxin) 
Heart rate reserve (bpm) 
Anti-arrhythmic therapy (excl. digoxin) 
Heart rate reserve (bpm) 
Amiodarone therapy 
Heart rate reserve (bpm) 
Peak VO2 (ml/kg/min) 
Heart rate reserve (bpm) 
NYHA class 
1.02 (1.01 -1 .03 ) 
4.2 (1 .9-9 .0) 
1.02 (1.01 - 1.04) 
3 .5 (1 .7 -7 .3 ) 
1.02(1.01 -1 .04 ) 
4.5 (2 .2-8 .9) 
1.02 (1.004-1.031) 
0.94 (0.89 - 0.99) 
1.02 (1.005-1.031) 
2.1 (1 .2-3 .5) 
0.0005 
0.0003 
0.0003 
0.0007 
0.0001 
<0.0001 
0.01 
0.02 
0.008 
0.006 
12.0 
13.4 
13.1 
11.4 
14.5 
18.0 
6.7 
5.4 
7.0 
7.7 
Multivariate Analysis 
Heart rate reserve (bpm) 1.02 (1.001 --1.031) 0.04 4.3 
Anti-arrhythmic therapy (incl. digoxin) 3.7 (1.7--8.0) 0.0009 11.0 
NYHA class 2.0 (1.2--3.4) 0.007 7.3 
Peak VO2 (mi/kg/min) NS -
Heart rate reserve (bpm) 0.98 (0.97--0.996) 0.01 6.3 
Amiodarone therapy 4.7 (2.4 --9.5) <0.0001 19.1 
NYHA class 2.1 (1.3--3.5) 0.002 9.4 
Peak VO2 (ml/kg/min)) NS -
NYHA class = New York Heart Association class, peak VO2 = peak oxygen consumption 
(ml/kg/min). 
* Hazard ratios for heart rate reserve and peak oxygen consumption are per beat per minute 
and one mi/kg/min, respectively. 
Table 2.7: Bivariate and multivariate predictors of mortality 
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2.6. Figures 
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Figure 2.1: Comparison between peak oxygen consumption (PVO2), oxygen 
pulse (Ozpulse) and ventilatory efficiency (VEA/COa-slope) between control 
subjects (Contr) and patients with transposition of the great arteries (TGA) 
after Mustard operation, patients with congenitally corrected TGA (ccTGA) 
and patients with univentricular heart (UVH). * P<0.05 compared with control 
subjects. 
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Figure 2.2: Examples of normal (A) and pathological (B-D) heart rate-oxygen 
uptake kinetics. The cross indicates predicted peak oxygen consumption 
(VO2) and peak heart rate. 
Panel A Normal (expected) linear relationship between heart rate and 
oxygen consumption in a healthy individual (Quadratic coefficient 7.8). 
Panel B 41 year-old male patient with congenitally corrected transposition of 
the great arteries (ccTGA) and markedly abnormal heart rate-oxygen 
consumption kinetics. Despite increase in heart rate, oxygen pulse is 
decreasing above a heart rate of 125 bpm. In addition, ST depression on 
ECG was noted at this stage (Quadratic coefficient 155). 
Panel C 25 year-old patient with bi-directional Glenn anastomosis. Resting 
saturations were 85% in room air. During exercise arterial oxygen saturations 
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dropped to 65%. This is reflected in an abnormal heart rate-oxygen 
consumption pattern, due to decreased arterio-venous oxygen difference 
during exercise (Quadratic coefficient 230). 
Panel D 27-year-old female-patient with classical Fontan for tricuspid atresia 
treated with Amiodarone for paroxysmal atrial arrhythmia. The heart rate 
does not increase above 130 beats per minute, however there is evidence of 
an increase in oxygen pulse. This pattern suggests exercise limitation due to 
impaired heart rate response to exercise (Quadratic coefficient -224V 
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Figure 2.3: Relationship between visual assessment of heart rate-oxygen 
uptake kinetics and calculated quadratic coefficient. The insert illustrates that 
a quadratic coefficient of 0 is equivalent with a linear relationship, whereas a 
negative or positive quadratic coefficient describe the curvature of the graph. 
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Figure 2.4: Heart rate and peak oxygen consumption (peak VO2) witli pre-
existing pacemaker (PIVl) settings and after active reprogramming. 
One patient (marked with an asterisk) developed atrial tachycardia at the test 
with pre-existing pacemaker settings. 
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Figure 2.5: Heart rate and oxygen consumption (VO2) versus heart rate plots 
(including oxygen pulse isopleths with corresponding oxygen pulse values 
given on the right) recorded from a healthy control subject (left panel) and a 
patient with systemic right ventricle (right panel). The plots illustrate the 
normal (expected) linear relationship between heart rate and oxygen 
consumption in the control subject and pathological heart rate-to-oxygen-
uptake kinetics in the patient. Despite increase in heart rate the patient is 
unable to increase oxygen uptake above a heart rate of approximately 130 
beats per minute resulting in a curvilinear heart rate-to-oxygen- uptake 
kinetics. 
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Figure 2.6: Comparison between systemic riglit ventricular total isovolumic 
time (t-IVT), total filling time (t-FT) and aortic velocity time integral (VTI) at 3 
different heart rates (HR). Non-parametric Wilcoxon tests (paired samples) 
were used to compare data. 
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Figure 2.7: Superimposed aortic and tricuspid Doppler recordings from a 
patient with a systemic right ventricle at 3 different heart rates. The 2 
components of total isovolumic time (t-IVT) are shaded. ECG indicates 
electrocardiogram, Phono, phonocardiogram; t-FT, total filling time, VTI, 
aortic velocity time integral. 
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Figure 2.8: Kaplan-Meier-Estimates of deatii from any cause among adult 
congenital heart disease patients stratified by quartiles of heart rate reserve. 
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Figure 2.9: A) Increase in heart rate during exercise - heart rate reserve, 
and B) decrease in heart rate at the end of exercise - heart rate recovery -
in surviving and non-surviving patients. Error bars indicate 95% confidence 
intervals. 
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2.7. Discussion 
Given that increase in heart rate during exercise mirrors increase in cardiac 
output, heart rate at maximal exertion has received considerable interest. 
Astrand and Rhyming (83) described a close correlation between heart rate 
during submaximal work and maximal oxygen uptake. Other authors have 
expanded upon this work providing a number of formulas to predict maximal 
heart rate during exercise (16,17,84,85). The term chronotropic 
incompetence - implying that the heart's response to exercise is not 
physiological - was introduced in 1975 by Ellestad and colleagues (86). The 
authors analysed follow-up results of 2700 patients who had undergone 
treadmill testing. They found that those with a blunted heart rate response to 
exercise were at greater risk for cardiac events compared to those with 
ischemic ST depression (87). In 1991 the American College of Cardiology 
and the American Heart Association recommended implantation of rate-
responsive pacemakers in patients who fail to reach a heart rate of 100 beats 
per minute at maximal exertion (88). However in subsequent guidelines the 
definition of chronotropic incompetence was revised and chronotropic 
incompetence vaguely defined as the inability to increase heart rate 
"appropriately with exercise" (89). Recently chronotropic incompetence has 
been defined as the inability to achieve a maximal predicted heart rate 
(MPHR) or reaching a given percentage (e.g. 85%) of MPHR during 
exercise. This approach is mainly limited by the lack of a formula that 
provides an accurate prediction of MPHR. Depending on the formula used 
errors in MPHR estimation may be in excess of 11 beats per minute (90). 
Wilkoff and colleagues (72) described the mathematical relationship between 
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heart rate and oxygen uptake termed the metabolic-chronotropic relation. 
Based on these findings Lauer and colleagues (13) derived the chronotropic 
index, (peak heart rate - resting heart rate) / (220 - age - resting heart rate) 
by applying the metabolic-chronotropic relation concept to a symptom limited 
exercise test. This allowed definition of the normal chronotropic response 
independently of age, resting heart rate and functional state (72). In a group 
of 410 healthy adults Wilkoff et al. (72) reported 95% limits of normality of 
chronotropic index to be 0.8 - 1.3. Based on these findings, chronotropic 
incompetence can be defined statistically as failure to achieve a chronotropic 
index of 0.8 (i.e. falling below 97.5% of healthy adults). 
The reported prevalence of chronotropic incompetence ranges between 30% 
in patients with chronic heart failure (18) to 60% in patients with chronic atrial 
fibrillation (91). In the current study chronotropic incompetence was found to 
be prevalent, affecting 62% of ACHD patients. The prevalence of 
chronotropic incompetence was lowest in patients with simple lesions such 
as repaired ventricular septal defect and was highest in patients with 
complex, uncorrected and cyanotic lesions. This increase in prevalence of 
chronotropic incompetence parallels the decline in peak oxygen consumption 
across the spectrum of ACHD. 
Previous studies have suggested that a blunted heart rate response may in 
part account for the reduced exercise capacity seen in ACHD patients (2). 
However, consistent with studies in various cardiovascular cohorts (2,18), 
the correlation between heart rate and exercise capacity is modest. 
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explaining only a quarter of the variation in peak oxygen consumption. This 
study demonstrates that cardiopulmonary exercise testing with measurement 
of oxygen pulse kinetics identifies a subgroup of patients with distinctively 
abnormal pattern of cardiovascular response to exertion and may allow the 
recognition of patients in whom chronotropic incompetence is causally 
related to exercise intolerance. Assessing oxygen uptake kinetics in 
individual patients, the results of this study suggest that a blunted heart rate 
response to exercise is responsible for reduced exercise tolerance in 
approximately 20% of ACHD patients. It therefore appears that heart rate 
response during exercise does not account for 1/5 of peak oxygen 
consumption in each patient, but in fact determines exercise capacity almost 
entirely in subgroup of patients, while it may be largely unrelated to peak 
oxygen consumption in others. As a consequence additional parameters 
such as age, sex, pulmonary function, cyanosis and peripheral factors 
determine exercise capacity in ACHD patients. 
The notion that blunted heart rate response may not be causally related to 
reduced oxygen uptake in many patients could be confirmed mechanistically 
in a subgroup of ACHD patients (those with a systemic right ventricle and a 
pre-existing pacemaker). Active reprogramming of the pre-existent 
pacemaker did not result in improved exercise capacity in these patients. 
Artificially increasing peak heart rate in itself was complicated in some 
patients and even in those in whom peak heart rate could be successfully 
augmented this intervention did not lead to a clinically relevant increase in 
peak oxygen consumption. The echocardiographic assessment of the timing 
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of the cardiac cycle at baseline and during higher heart rates provides an 
physiologic insight into the mechanisms potentially responsible for the 
discrepancy between high heart rates and low VO2 in these patients: Heart 
rate increase leads to a significant reduction in total filling time and a 
significant increase in total isovolumic time accompanied by a marked 
reduction of aortic VTI (a surrogate parameter of stroke volume). This is in 
contrast to data published in healthy individuals showing an increase in total 
filling time and a reduction in total isovolumic time with increasing heart rate 
during dobutamine stress (92). 
Total isovolumic time - the time where the ventricle neither ejects nor fills -
has been shown to be prolonged in patients with myocardial ischemia and 
has been linked to mechanical incoordination (93). Both, limited coronary 
flow reserve and mechanical incoordinaton during pharmacological stress 
have been reported previously in patients with a systemic right ventricle 
(10,78). It appears likely, therefore, that the increase in total isovolumic time 
with increasing heart rate in these patients reflects myocardial ischemia and 
mechanical incoordination. This notion is supported by the fact that 
increasing heart rate during exercise was not accompanied by an increase in 
VO2 in the majority of patients (Figure 2.5), a well recognized feature of 
myocardial ischemia in acquired heart disease (94). The increase in t-IVT in 
turn leads to a reduction in total filling time finally resulting in a reduction in 
stroke volume as indicated by reduced aortic VTI (Figure 2.6). Derrick and 
colleagues reported a limitation in stroke volume augmentation during 
exercise and dobutamine stress resulting from impaired atrio-ventricular 
transport potentially reflecting anatomical and functional abnormalities of the 
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atrio-ventricular pathways after the Mustard operation (95). This suggests 
that there may be two mechanisms limiting stroke volume during heart rate 
increase in patients with a systemic right ventricle. 
The aetiology of chronotropic incompetence in patients with cardiovascular 
disorders is not fully understood. It appears likely that chronotropic 
incompetence is a multifactorial phenomenon. Colluci and colleagues (96) 
reported that impaired chronotropic response to exercise in patients with 
chronic heart failure is, at least in part, due to postsynaptic desensitization of 
p-adrenergic receptors. Others have demonstrated that autonomic function is 
significantly decreased in patients with acquired heart disease who are 
chronotropically incompetent (97,98). In addition, conduction disease as part 
of the natural history or as a consequence of previous surgery is common in 
ACHD patients and anti-arrhythmic drug therapy is commonly required in this 
population. 
The prognostic value of an inappropriate increase in heart rate during 
exercise has been well established in various cardiovascular cohorts (11) 
and in healthy individuals(12,14,99). 
This study demonstrates that chronotropic incompetence predicts an 
enhanced mortality risk independently of anti-arrhythmic medication in ACHD 
patients. Moreover, even an attenuated rate of recovery of heart rate after 
exercise testing carries important prognostic information. Heart rate reserye -
a simple and easy to obtain parameter - was found to be a powerful 
prognostic marker in ACHD independently of anti-arrhythmic medication and 
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peak oxygen uptake. Stratifying patients by diagnostic groups revealed that 
a lower heart rate reserve was also associated with a greater risk of death in 
patients with complex anatomy, Fontan circulation and tetralogy of Fallot. 
Furthermore, a combination of heart rate reserve and peak oxygen 
consumption identifies a subpopulation of ACHD patients with a 3.8 fold 
increase in mortality. 
2.8. Limitations 
This work cannot identify why chronotropic incompetence predicts poor 
prognosis in ACHD patients. It is also possible that the low chronotropic 
index in some patients included in the current study was due to inadequate 
effort. However, reference values are based on comparable cohorts of 
healthy subjects undergoing symptom limited exercise testing. 
Of necessity, the number of patients with a systemic right ventricle and a pre-
existing pacemaker in this single-centre study was small. Moreover, two 
patients with congenitally corrected transposition of the great arteries were 
included who in contrast to the 7 patients with atrial switch procedure did not 
have atrial surgery potentially limiting their atrio-ventricular transport 
capacity. However, when these patients were excluded the results of the 
study did not change. 
Echocardiographic assessment was performed at resting heart rate and after 
artificially increasing heart rate by pacemaker reprogramming. It is likely that 
the results of the study do not fully reflect the physiologic changes occurring 
during physical exercise. These include inotropic activation, peripheral 
vasodilatation and increased venous return. Nevertheless, the findings of the 
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current study findings are consistent with previous data in patients with 
systemic right ventricle studied during pharmacological stress and exercise 
showing comparable abnormalities. Finally, conventional ventricular pacing 
may - in itself - induce incoordination and thereby limiting total isovolumic 
time especially at higher heart rates and this requires further studies. 
2.9. Conclusion 
An abnormal heart rate response to exercise is prevalent across the 
spectrum of adult congenital heart disease, and is associated with an 
enhanced risk of death. Even on its own, heart rate reserve has the potential 
as a simple means to identify ACHD patients at elevated risk. In combination 
with formal measurement of peak oxygen consumption, it identifies a 
subpopulation with a 3.8 fold elevated risk of death in the midterm. 
Assessing oxygen pulse kinetics visually or by polynomial regression 
analysis may be valuable in identifying patients in whom an attenuated heart-
rate response is responsible for poor exercise capacity. Furthermore, this 
study suggests that despite inappropriate heart rate response to exercise 
(chronotropic incompetence) optimized rate responsive pacing does not 
improve objective exercise capacity in patients with a systemic right ventricle. 
The results of this study rather indicate that higher heart rates may be 
detrimental in these patients by prolonging isovolumic time and reducing 
diastolic filling time. These findings may have clinical implications when 
considering implantation of a permanent pacemaker in a patient with a 
systemic right ventricle. 
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Chapter III Pulmonary vascular disease 
3.1. Background of the study 
Pulmonary arterial hypertension (PAH) — an elevated mean pulmonary 
arterial pressure of more than 25 mmHg at rest or 30 mmHg on exercise — 
is commonly associated with congenital heart disease (100). It has been 
estimated that approximately 5-10% of patients with congenital heart disease 
develop PAH (101-103). Eisenmenger syndrome represents the extreme 
manifestation of PAH in adult congenital heart disease (ACHD) patients and 
has become the epitome of severe PAH in this setting (104-107). It has been 
recently demonstrated that patients with Eisenmenger syndrome as a group 
exhibit the lowest exercise tolerance among adult patients with congenital 
heart disease (Figure 3.1) (1). Furthermore, on uni- and multivariate analysis 
the presence of PAH and cyanosis emerged as important determinants of 
peak oxygen consumption (Cyanosis r=-0.41, 95% confidence interval [CI] -
0.31 - -0.50, P<0.0001: PAH r=-0.38, 95% CI -0.28- -0.47, P<0.0001). 
Perhaps not surprisingly the combination of PAH and cyanosis - as in 
patients with Eisenmenger physiology - severely limits exercise capacity 
(108). 
This series of studies examined the prevalence of Eisenmenger syndrome 
amongst patients followed-up at a tertiary centre for adult congenital heart 
disease, provided a contemporary overview of adult patients with 
Eisenmenger physiology, examined their exercise capacity and assessed 
survival prospects as well as risk factors for mortality. In addition the impact 
of Bosentan (a pulmonary vasodilator) on exercise capacity was examined 
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during longer-term follow-up in patients with pulmonary arterial hypertension 
associated with congenital heart disease. 
3.2. Impact of Eisenmenger syndrome on exercise tolerance and 
survival in adults with congenital heart disease 
This study aimed to provide an overview of adult congenital heart disease 
patients with Eisenmenger syndrome followed at the Adult Congenital Heart 
Unit, Royal Brompton Hospital, London, to assess symptoms and exercise 
capacity in this cohort as well as to investigate survival prospects and risk 
factors for mortality. To provide an overview of the patient characteristics a 
cross-sectional study was performed. This retrospective analysis was 
combined with a case-control study to investigate risk factors for mortality. 
Despite utilizing a smaller number of patients overall, case control studies 
include all patients with adverse outcome and may be adjusted for known 
confounders such as age and underlying diagnosis. 
3.2.1. Methods 
Retrospective analysis 
This was a retrospective study. All patients with Eisenmenger physiology 
under regular follow-up were identified from the computerized database of 
patients with adult congenital heart disease followed-up at the Adult 
Congenital Heart Disease unit, Royal Brompton Hospital, London. Inclusion 
criteria were evidence of pulmonary hypertension (confirmed by 
echocardiography and/or cardiac catheterisation) in the presence of a large 
unrestrictive atrial or ventricular septal defect or aorto-pulmonary 
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communication as previously described (105). Patients who had undergone 
shunt closure previously and those with restrictive shunts unlikely to be 
related to pulmonary hypertension were excluded. For the retrospective 
analysis the data of the first full assessment within the study period was 
Included. 
Case control study 
The patient population was screened for deaths occurring in Eisenmenger 
patients between 2000 and 2005. Each patient who died was matched with a 
surviving control patient of similar age (within 7 years) and underlying 
anatomy. Medical records were reviewed and underlying characteristics, 
including diagnosis, ECG parameters, echocardiographic findings and 
laboratory results were recorded. For the case control study data from the 
last clinical visit were recorded for mortality cases, whereas for surviving 
control patients data around the time of the last clinical visit of the 
corresponding mortality case (within 6 months) were acquired. Risk factors 
considered included: functional (NYHA) class, deterioration in NYHA class 
(deterioration of at least one functional class within the last year before the 
clinical visit), need for more aggressive drug therapy (diuretics and anti-
arrhythmic drugs) within the last year before the clinical visit, presence of 
clinical signs of heart failure (peripheral oedema or ascites), history of 
documented clinical arrhythmia, ECG parameters (such as underlying 
rhythm, QRS duration, QT and QTc interval), laboratory parameters (such as 
serum electrolytes, creatinine, albumin, liver function tests), cardiac 
medication, history of pulmonary or systemic emboli, history of pulmonary 
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infections and/or haemoptysis as well as history of near-syncope or syncope. 
In addition, systemic and subpulmonary systolic ventricular function and 
dimensions were assessed semiquantitatively from transthoracic 
echocardiograms, and quantified as previously described. Iron deficiency 
was defined as a ferritin level <15 ng/ml or a transferrin saturation < 15%. In 
patients where there was discrepancy between these values, transferrin 
saturation was considered paramount. 
Statistical analysis 
Values are presented as mean ± standard deviation. Comparisons between 
groups were made using Student's t test, Mann-Whitney U test or Chi-
squared test as appropriate. Kaplan-Meier survival curves were constructed 
to illustrate the survival of Eisenmenger patients. Survival prospects were 
compared to those predicted for an age and gender matched healthy cohort 
of UK residents using life table data (2001-2003 Interim life tables) published 
by the Government Actuary's Department (http://www.gad.gov.uk) as 
described previously (109). 
Risk factors for death were identified by univariate conditional regression 
analysis. Odds ratios and 95% confidence intervals for significant predictors 
were reported. R version 2.1.1. and MedCalc 8.1 (MedCalc Software, 
Mariakerke, Belgium) were used for statistical analysis. For all analyses, a 2-
sided P-value of less than 0.05 was considered statistically significant. 
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3.2.2. Results 
Patient population 
Overall, 171 patients (115 female, 56 male) fulfilled inclusion criteria and 
were included. The mean age at the last visit was 37±12 years (range 14-72 
years). Ninety-seven patients (57%) had simple anatomy (12 atrial septal 
defect, 63 ventricular septal defect, 22 patent arterial duct) while 74 patients 
(44%) had complex anatomy, comprising atrioventricular septal defects, 
"univentricular heart", transposition of the great arteries and common arterial 
trunk. There were 48 patients with Down's syndrome (28%). Down patients 
were significantly younger compared to the remaining patients (30±9 vs. 
40±12 years, P<0.001). The majority of the patients were symptomatic 
(94%), whereas only 6% of patients reported no symptoms. Classifying 
symptoms according to the NYHA classification revealed that 6% of patients 
were in functional class I, 48% in class II, 42% in class III and only 4% were 
in class IV. When patients were stratified according to the location of 
shunting, no significant difference in symptoms could be found: symptoms 
corresponding to NYHA class III or above were found in 54% of patients with 
atrial shunt, 54% of patients with a shunt at ventricular level and 57% of 
patients with aorto-pulmonary shunt (P=0.96). 
Mean oxygen saturation in room air was 84±8%, lower in patients with higher 
NYHA class (81 ±7% in patients with NYHA class III or IV vs. 86+8 in patients 
with NYHA class I or II, P<0.001) and in those with complex anatomy 
(82±8% in patients with complex lesions vs. 85±8% in patients with simple 
lesions, P=0.006). 
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The majority of patients were in sinus rhythm (98%) at the last visit, whereas 
only 2% of patients were in atrial fibrillation (n=2) or had a pacemaker rhythm 
(n=2, for complete heart block). A clinical history of arrhythmia requiring 
cardioversion or anti-arrhythmic therapy was documented in a minority of 
patients (13%). Palpitations, however, were more common, and were 
present in 44 patients (26%). Furthermore, 23 patients (13%) experienced at 
least one syncopal episode during the follow-up period. 
Dizziness was reported by 25 patients (15%) and was related to history of 
syncope, independent of age and survival status (P<0.001). Thirty-five 
patients had a history of haemoptysis. Patients with haemoptysis were more 
likely to be anticoagulated with warfarin (P=0.04). In addition, patients in a 
higher functional class were more likely to have clinical signs of heart failure, 
independent of age and survival status (P=0.003). 
Medication 
Twenty-three patients were treated with a beta-blocker, 19 patients with an 
ACE-inhibitor, 7 with a calcium-antagonist and 17 patients with digoxin. 
Forty-six patients received diuretics. Twenty patients were treated with 
potassium-sparing diuretics such as spironolactone or amiloride. Only one 
patient (with the lowest potassium level) was treated in our hospital with 
potassium supplements. Forty-nine patients were anti-coagulated with 
warfarin, while 17 patients were treated with anti-arrhythmic drugs. In 
addition 39 patients had home oxygen therapy and 20 patients were treated 
with advanced therapies for pulmonary hypertension (18 with Bosentan - an 
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endothelin antagonist, 1 patients with Sildenafil - a phosphodlesterase-5-
inhibitor, and 1 with a combination of both). 
Laboratory measures, haematology and iron deficiency 
Laboratory results were available in 129 patients. Mean potassium level was 
4.3±0.5 mmol/L (range 3.1-5.7 mmol/L). Mean haemoglobin concentration 
was 19.2+3.2 g/dl (range 10.1 - 26.1 g/dl). Iron deficiency was found In 24 
patients. Twenty-nine patients had a history of phlebotomy. Phlebotomy was 
strongly associated with the presence of iron deficiency (relative risk 4.1, 
95% confidence interval 2.2 - 7.7, P<0.0001). There was an inverse 
relationship between resting oxygen saturations and haemoglobin levels in 
patients without iron deficiency as shown in Figure 3.2. However, no such 
relationship could be found in patients with iron deficiency. 
Survival analysis 
During a median follow-up period of 67 months (range 8 - 68), 20 patients 
died. Nine patients died in progressive heart failure (45%), while 11 patients 
(55%) died unexpected, presumably suddenly. These numbers are 
comparable with those reported by Niwa et al (110), where 63% of patients 
died suddenly. Survival at 30, 40, 50 and 60 years of age was 98%, 94%, 
74%, and 52%, respectively (Figure 3.3). Patients with complex anatomy had 
a significantly worse prognosis compared to those with simple anatomy 
(P=0.02). While 50% of patients with simple anatomy were still alive at 58 
years of age, 50% of those with complex anatomy had died by the age of 42 
years, as demonstrated in Figure 3.4. In addition, this figure also shows the 
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estimated survival curve for a gender-matched cohort of healthy individuals 
based on Life Tables for England and Wales (2001-2003) published by the 
Government Actuary's Department. Survival was significantly worse for 
Eisenmenger patients than expected for a matched healthy cohort 
(standardised mortality ratio 3.8; 95% confidence interval 2.0 - 7.0; 
P<0.0001). While 20 patients Eisenmenger patients died during follow-up, 
the expected mortality in the matched population was only 5.3 deaths. 
Predictors of mortality 
Twenty patients died (8 male) and were included into the case control study. 
Underlying cardiac anatomy was a non-restrictive ventricular septal defect 
(VSD) in 5, atrial septal defect in 4, common arterial trunk in 4, transposition 
of great arteries with VSD in 3 and patent arterial duct in 4. Mean age at 
death was 43.2±10.5 years. 
On conditional logistic regression analysis, functional (NYHA) class (odds 
ratio = 3.37, 95% confidence interval [CI] 1.05 - 10.8, P=0.041) and 
presence of signs of heart failure (odds ratio = 9.00, 95% CI 1.14 - 71.04, 
P=0.037) were found to be predictive of death. On ECG, longer QRS 
duration (odds ratio = 1.10/ms, 95% CI 1.002 - 1.199/ms, P=0.044) and 
longer QTc interval (odds ratio = 1.07, 95% CI 1.001 - 1.151/ms, P=0.047) 
were associated with a worse outcome. Low serum albumin (odds ratio = 
0.84/gL-1, 95% CI 0.71 - 0.99/ gL-1, P=0.034) and low potassium levels 
(odds ratio = 0.06/ mmolL-1, 95% CI 0.004 - 0.960/mmolL-1, P=0.047) were 
also predictive of death. 
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In addition, a history of clinical arrhythmia (odds ratio = 9.00, 95% CI 1.14 -
71.03, P=0.037), deteriorating NYHA class (odds ratio = 11.00, 95% C11.42 
- 85.20, P=0.022) as well as need for more aggressive drug therapy (odds 
ratio 9.00, 95% CI 1.14-71.03, P=0.037) within one year before the last 
clinic visit were all predictive of poor outcome. 
In contrast, neither medication nor semi-quantitative echocardiographic 
assessment of right and left ventricular size and function were predictive of 
death. Furthermore, previous history of pulmonary or systemic emboli, 
recurrent pulmonary infections or haemoptysis and near-syncope or syncope 
was not significantly different between the two outcome groups. 
3.3. Impact of Bosentan therapy on exercise capacity in patients with 
congenita! heart disease and pulmonary arterial hypertension 
Exercise capacity is greatly diminished in patients with Eisenmenger 
syndrome. In practice, >90% of patients are in New York Heart Association 
class 2 or above, and approximately 50% report severe limitation (New York 
Heat Association class 3 or 4). Bosentan, a dual-receptor endothelin 
antagonist and pulmonary vasodilator, has an established role in the 
management of patients with idiopathic pulmonary arterial hypertension 
(PAH). This study aimed to assess safety profile and clinical effects of 
Bosentan in adults with PAH and congenital heart disease during longer-term 
follow-up. 
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3.3.1. Methods 
Patient characteristics 
All adult patients with significant pulmonary hypertension (as defined by 
current guidelines(54)) associated with congenital heart disease or with 
Eisenmenger syndrome who were treated with Bosentan at the Adult 
Congenital Heart Disease Program, Royal Brompton Hospital, London were 
included in this retrospective analysis. A subgroup of patients (n=10) was 
included in a previous prospective short-term (16 weeks) safety and 
tolerability study of Bosentan (111) and these patients were subsequently 
continued on Bosentan on compassionate grounds. Medical records were 
reviewed and underlying demographics as well as clinical characteristics 
were recorded. Additional parameters analysed at baseline and during 
follow-up included: functional class, oxygen saturation in room air, 6-minute 
walk test distance, ECG related parameters and liver function tests. 
Treatment with Bosentan as part of clinical studies was approved by the local 
ethics committee and these patients provided informed consent before 
commencement of therapy. 
Medication 
At the Adult Congenital Heart Unit, Royal Brompton Hospital, London a 
policy of commencing therapy with 62.5 mg twice daily, increased to 125 mg 
twice a day after 4 weeks, as tolerated is operated. Bosentan therapy is 
initiated in hospital with close monitoring of oxygen saturations as well as 
blood pressure as described previously (111). 
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Electrocardiographic parameters and six-minute wall< test 
Electrocardiograms were reviewed and a voltage criterion for right ventricular 
hypertrophy was derived as the sum of the R-wave amplitude in Vi and the 
maximum amplitude of the S-wave in either V5 or Ve. Amplitudes on ECG 
were measured by two independent investigators blinded towards date of the 
ECG (baseline vs. therapy). 
Statistical analysis 
Values are presented as mean ± standard deviation. Unless stated 
otherwise, comparisons between baseline and follow-up groups were made 
using non-parametric tests (Wilcoxon's paired rank test or McNemar test). 
MedCalc Version 8.1 (IVledCalc, Mariakerke, Belgium) was used for 
statistical analysis. For all analyses a P-value of less than 0.05 was 
considered statistically significant. 
3.3.2. Results 
Demographics 
Overall, 18 (14 female) patients fulfilled inclusion criteria and were included 
in the study. Average age at commencement of Bosentan therapy was 41 ±9 
years (range 23 - 69 years). Median follow-up was 29 months (range 1-39 
months) as shown in Figure 3.5. Underlying diagnoses were: simple lesions 
in 12 patients (large atrial septal defect in 2, non-restrictive ventricular septal 
defect in 7, persistent arterial duct in 2, aortopulmonary window in 1), and 
complex lesions in 6 patients (atrio-ventricular septal defect in 2, "single 
ventricle" physiology in 3, and double discordance with non-restrictive VSD in 
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1). Fifteen patients did not undergo any previous corrective surgery and 
constituted tine Eisenmenger group, while three patients had undergone 
corrective surgery late in infancy and subsequently developed secondary 
pulmonary arterial hypertension. 
Safety and tolerability 
All but one patient received 125 mg Bosentan twice a day after the initial up-
titration period. One patient had noticed subjective improvement with the 
initial dose of 62.5 mg Bosentan twice daily, however she experienced 
lightheadedness after uptitration to 125 mg Bosentan and was therefore 
downtitrated to 62.5 mg Bosentan twice daily. None of the patients needed 
discontinuation of Bosentan therapy due to untoward effects. One patient 
was hospitalized early after commencement of Bosentan treatment due to a 
chest infection that resolved with appropriate antibiotic therapy. 
No significant rise in liver transaminases was observed during follow-up 
(Figure 3.6). None of the patients exhibited elevation of transaminase values 
exceeding three times the upper limit of the reference range. Furthermore, 
transaminase values did not further increase during Bosentan therapy even 
in patients with elevated liver enzyme levels at baseline. 
One patient died during follow-up. This was a 69-year-old female patient with 
"single ventricle" physiology and unprotected pulmonary circulation (situs 
solitus, double inlet left ventricle, rudimentary right ventricle, discordant 
ventriculo-arterial connection and a non-restrictive inlet ventricular septal 
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defect) who was commenced on Bosentan on compassionate grounds 
following marked deterioration in functional class. The patient who reported 
symptomatic improvement on Bosentan therapy, died 11 months later due to 
respiratory insufficiency and progressive heart failure. 
Oxygen saturations 
There was no significant drop in oxygen saturations, neither within the first 
six months of therapy, nor during longer-term follow up. Arterial saturations in 
Eisenmenger patients increased compared to baseline early during therapy 
(81.1±4.9% vs. 84.7±2.6%, P=0.014). At 1 and 2 years of follow-up oxygen 
saturations were higher compared to baseline, however the difference was 
not significant (81.1±4.9% vs. 84.5±2.8, P=0.054; and, 81.1±4.9% vs. 
84.2±4.8, P=0.078, respectively) as shown in Figure 3.7. 
Six-minute wall< test distance 
Six-minute walk test distance improved significantly during Bosentan therapy 
compared to baseline (284±144 vs. 363±124, 380±91, and 408±114 m at 
baseline, 0-6 months, 6-12 months and 1-2 years of therapy, respectively; 
P<0.05 for each) as shown in Figure 3.8. In addition, during the first 6 
months of therapy 70% of patients improved their 6 minute walk distance by 
more than 54m, an improvement associated with a noticeable clinical 
difference in the patients' perception of exercise capacity as recently defined 
by the American Thoracic Society. 
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Consistent witli this objective improvement in exercise capacity, patients' 
perceived functional class improved during follow-up (P=0.001). In fact, 11 
patients improved in their functional class during therapy, while the remaining 
7 patients remained stable. None of the patients felt subjectively worse on 
Bosentan therapy. 
Electrocardiographic findings 
Voltage criteria for right ventricular hypertrophy (sum of the R-wave 
amplitude in VI and the maximum amplitude of S in either V5 or V6) 
improved significantly during Bosentan therapy (21.9 ± 6.9 vs. 19.7 ± 6.1 mV; 
P=0.01: median time between baseline and follow-up ECG of 11 months). 
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3.4. Figures 
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ASD = atrial septal defect; ccTGA = congenitally corrected transposition of the great arteries; 
SD = standard deviation; VSD = ventricular septal defect. 
Figure 3.1: Distribution of peak oxygen consumption (peak V02) in different 
diagnostic groups among 335 adult congenital heart disease patients. 
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Figure 3.2: Association between resting oxygen saturation in air (%) and 
haemoglobin concentration stratified by iron deficient and iron replete 
patients. While no relationship between arterial saturations and haemoglobin 
concentrations was found in iron deficient patients, arterial saturations and 
haemoglobin concentrations were inversely related in iron replete patients. 
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Figure 3.3: Survival as a function of follow-up time (left) and as a function of 
age (right) in patients with Eisenmenger physiology, illustrating that while 
short-term prognosis is relatively good, overall life expectancy is reduced in 
Eisenmenger patients. 
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Figure 3.4: Survival prospects of patients with Eisenmenger physiology 
compared to an age and gender matched healthy population showing 
reduced life expectancy in patients with Eisenmenger syndrome. The 
survival curve appears to be shifted leftwards by approximately 20 years in 
patients with simple underlying lesions and approximately 40 years in those 
with complex lesions. 
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Figure 3.5: Date of commencement and duration of Bosentan therapy. One 
patient (+) aged 69 years with complex congenital heart disease died due to 
combined respiratory and right heart failure. Follow-up was complete for all 
patients. 
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Figure 3.6: Serum levels of aspartate (AST) or alanine (ALT) 
aminotransferase as markers of hepatic function at baseline and during 
follow-up. 
Comparisons were made between baseline and follow-up values using a 
non-parametric test (Wilcoxon paired rank test). 
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Figure 3.7: Oxygen saturation at rest in room air at baseline and during 
follow-up. * Comparisons were made to baseline using a non-parametric test 
(Wilcoxon paired rank test). CHD = congenital heart disease. PAH = 
pulmonary arterial hypertension. 
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Figure 3.8: Six minute walk test distance at baseline and during follow-up. 
* Comparisons were made to baseline using a non-parametric test (Wilcoxon 
paired rank test). 
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3.5. Discussion 
Information on characteristics and prognostic variables is limited in 
contemporary Eisenmenger patients. In a retrospective study, Cantor et al. 
(1999) reported predictors of death in Eisenmenger patients referred for lung 
transplantation, while Daliento et al (1998) characterised 188 Eisenmenger 
patients followed-up at 3 different European centres over 3 decades 
(112,113). The current study was performed at a single centre, thus avoiding 
differing management strategies at different centres, included only 
contemporary patients - reflecting current practice - and is the first case 
control study in this population. 
Exercise capacity is markedly depressed in adult patients with Eisenmenger 
syndrome. This study shows that >90% of Eisenmenger patients had 
symptoms equivalent to New York Heart Association class II or above. A 
higher functional class was related to lower resting arterial oxygen 
saturations and a higher incidence of ascites or peripheral oedema. In 
contrast to previous reports (106), this study could not confirm a relationship 
between the location of shunting and degree of physical limitation. Overall, 
less than 10% of Eisenmenger patients were treated with standard heart 
failure medication such as beta-blockers, ACE inhibitors or calcium 
antagonists. This is likely to reflect the lack of evidence for a beneficial effect 
of these therapies in this cohort as well as the fear that these drugs may 
induce systemic vasodilation with subsequent increase in right-to-left 
shunting. In contrast, 19 patients were treated with disease targeting 
therapies for pulmonary hypertension (endothelin receptor or 
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phosphodiesterase-5 antagonists) as part of ongoing clinical studies or on a 
compassionate basis. Twenty-three percent of patients were treated with 
home oxygen. Data regarding the chronic use of oxygen in patients with 
Eisenmenger syndrome is inconsistent (114,115), however some patients 
benefit and home oxygen should be used in individual patients. 
Formal exercise testing provides information on objective exercise capacity 
and insight into the factors limiting exercise capacity (such as change in 
arterial oxygen saturation during exercise). Exercise capacity is either 
assessed by measurement of 6-minute walk test distance or 
cardiopulmonary exercise testing with measurement of parameters of gas 
exchange. Both modalities have been used successfully to assess exercise 
intolerance in patients with PAH of various aetiology (1). Impaired peak 
oxygen uptake and reduced 6-minute walk test distance have been reported 
to be related to impaired prognosis in this setting (116-118). In most centres 
the 6-minute walk test represents the preferred modality to assess patients 
with PAH. The 6-minute walk test is robust, cheap and unlike 
cardiopulmonary exercise testing with measurement of parameters of gas 
exchange does not require sophisticated equipment or special expertise. For 
reasons discussed in detail elsewhere the 6-minute walk test is the only 
exercise modality approved by the US Food and Drug Administration as an 
end point in clinical trials in the setting of PAH (119-121). 
The vast majority of Eisenmenger patients in this study had secondary 
erythrocytosis as reflected by elevated mean haemoglobin concentrations. 
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This represents an adaptation to cyanosis. In the present study a strong 
association between arterial oxygen saturations and haemoglobin values 
was found in iron replete patients. In contrast no such association could be 
found in iron deficient patients suggesting that iron deficient patients were 
unable to increase their haemoglobin concentrations in proportion to reduced 
arterial oxygen saturations, thus failing to maintain oxygen carrying capacity 
of the blood (Figure 3.2). Consistent with previous studies the presence of 
iron deficiency was linked to routine phlebotomies (relative risk 
approximately 4). Routine phlebotomy is therefore discouraged at most 
centres in patients with Eisenmenger syndrome due to well recognized 
complications such as iron deficient anaemia and increased risk for 
cerebrovascular accidents (31). In addition, iron deficiency should be 
promptly treated with oral iron supplementation (or intravenous, if oral 
therapy fails). 
Haemoptysis is a well recognized complication of Eisenmenger syndrome. In 
the current study a history of haemoptysis was found in 20% of patients. This 
is consistent with previously reported incidence rates, ranging between 11% 
and 33% (106,110,112). In the current study haemoptysis was not related to 
anaemia or an increased risk of death. This is consistent with the results 
published by Daliento in 1998 (113). In this study an association between 
haemoptysis and anticoagulation therapy was present. However, some 
patients are anticoagulated for pulmonary arterial thrombosis, which in itself 
is often associated with haemoptysis due to pulmonary infarction (105,122). 
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Therefore, the relationship between anticoagulation and haemoptysis may be 
confounded in this population. 
Life expectancy in contemporary patients with Eisenmenger physiology was 
found to be reduced by approximately 20 years and mortality risk increased 
3.8 fold compared to the general population. In agreement with previous 
studies, however, short-term mortality was found to be low (12.5% at 5 
years) (112,113), supporting the notion that survival prospects in 
Eisenmenger patients are better than previously appreciated and are far 
superior to those observed in patients with idiopathic pulmonary 
hypertension (123). Survival prospects were significantly poorer in patients 
with complex anatomy compared to those with simple underlying cardiac 
lesions. While 50% of patients with simple anatomy were still alive at the age 
of 58 years of age, 50% of those with complex anatomy had died by the age 
of 42 years. 
Signs and symptoms of heart failure (functional class and presence of 
oedema) were found to predict mortality in Eisenmenger patients. In addition, 
laboratory parameters related to impaired liver function - potentially linked to 
congestive heart failure - were also predictive of mortality. Furthermore a 
history of clinical arrhythmia was predictive of death. Low potassium 
concentrations, potentially associated with a greater risk of malignant tachy-
arrhythmias also carried prognostic information. In agreement with previous 
reports a higher functional class was found to be predictive of mortality 
(112,113). In contrast, data on the predictive value of arrhythmias is 
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conflicting: wliile Cantor and colleagues (112) found an association between 
history of arrhythmia and mortality, another report could not identify a link 
between history of arrhythmia and death (113). None of these previous 
studies describe an association between signs of heart failure and risk of 
death. The current study suggests that a history of syncope is not related to 
poor outcome. This is consistent with data published by Cantor et al. and 
Daliento et al. (112,113), the current study suggests that a history of syncope 
is not related to poor outcome in Eisenmenger patients. In contrast, earlier 
studies found syncope to be an predictor of mortality (105). Furthermore, in 
this study ECG parameters (QRS duration and QTc) were identified to be 
predictive of poor outcome in Eisenmenger patients. 
Traditionally treatment options for patients with PAH associated with 
congenital heart disease were limited to palliative measures and heart-lung 
transplantation in selected patients. In addition, as pointed out by Oechslin 
the 'mainstay of care is not to destabilize the balanced physiology' (27). 
Recently, however, this therapeutic nihilism has been challenged by the 
advent of effective drugs for the treatment of pulmonary hypertension 
(46,124,125), These therapies may also be applicable to patients with PAH 
with congenital heart disease and preliminary results are promising 
(126,127). 
Endothelin-1 - a potent vasoconstrictor and mitogen for vascular smooth 
muscle cells - is produced primarily by endothelial cells (128). Elevated 
systemic endothelin levels have been reported in patients with Eisenmenger 
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syndrome (129). In addition, endothelin-1-like immunoreactivity was 
reported in endothelial cells of pulmonary arteries of patients with primary 
and secondary PAH (130). Bosentan is a competitive endothelin receptor 
antagonist that inhibits binding of endothelin to its type A and B receptors. 
Bosentan has been demonstrated to reduce pulmonary arterial pressure, 
decrease pulmonary vascular hypertrophy and to attenuate pulmonary 
fibrosis and inflammation (131). Its efficacy In patients with Idiopathic 
pulmonary hypertension has been confirmed by two randomized controlled 
trials (46,47). Recently, the results of the first randomized study using 
Bosentan in patients with Eisenmenger syndrome (BREATHE-5) have been 
reported (132). BREATHE-5 was a multicenter, double-blind, randomised, 
placebo-controlled study safety study over 16 weeks that provided evidence 
that Bosentan is safe in this cohort and improves six-minute walk distance. 
Due to the relatively short follow-up period employed in this study, the long-
term effects of Bosentan remained largely unknown. 
The current study demonstrates that Bosentan is safe and well tolerated in 
patients with pulmonary hypertension associated with congenital heart 
disease not only during short- but also medium to long-term therapy. 
Exercise capacity, as assessed formally by six-minute walk test distance 
improved significantly and to a degree that is likely to be clinically relevant 
early during Bosentan therapy, and this effect was maintained throughout the 
study period. Furthermore, electrocardiographic evidence suggesting 
regression of right ventricular hypertrophy was found. 
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There was no evidence that oxygen saturations deteriorates during Bosentan 
therapy. In fact, a modest but statistically significant increase in oxygen 
saturation early during follow-up was found. These findings are consistent 
with results of previous studies (126,127,133). In none of the studies -
including the current one - the theoretical concern of an aggravated right-to-
left shunt induced by a fall in systemic vascular resistance as a consequence 
of vasodilator therapy was substantiated. Endothelin antagonists have been 
reported to cause dose-dependent hepatic dysfunction. In addition, 
Eisenmenger syndrome represents a multiorgan disease and thus hepatic 
injury may be of even greater concern in this cohort compared to patients 
with pulmonary arterial hypertension of different aetiologies. Monthly 
monitoring of aminotransferase levels is, thus a licensing requirement by 
both the European Agency for the Evaluation of Medicinal Products (EMEA) 
and the Food and Drug Administration (FDA) for these drugs. In the current 
study, no evidence of a clinically relevant elevation in serum levels of 
aspartate or alanine aminotransferase as markers of hepatic function was 
found. In addition, in none of the studied patients did these parameters 
exceed three-fold the upper reference value on Bosentan therapy. In 
previous studies hepatic dysfunction was primarily observed in patients 
treated with higher Bosentan doses (250 mg twice daily) compared to the 
doses routinely employed at our institution (134). Furthermore, none of the 
patients from the current study had to be discontinued from Bosentan 
therapy due to untoward effects. 
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A significant increase in six minute walk test distance early during therapy 
was found and this effect was sustained up to two years of Bosentan 
treatment as shown in Figure 3.8, It is noteworthy that the observed 
improvement in six minute walk test distance is likely to be clinically relevant 
in these very limited patients (1). In 70% of patients an increase in six minute 
walk test distance of > 54 meters was observed within 6 months of treatment. 
A recent guideline suggested that an improvement of this magnitude is 
associated with a perceivable improvement in exercise capacity by the 
patient (119). The findings of the current study concur with studies in patients 
with idiopathic pulmonary arterial hypertension, in which initial improvement 
in six minute walk test distance was sustained during long-term Bosentan 
treatment (135). Moreover, in agreement with the observed improvement in 
objective exercise capacity, symptomatic status improved during therapy. 
Recently, Schulze-Neick and colleagues reported improved six minute walk 
test distance in adult patients with Eisenmenger syndrome and pulmonary 
arterial hypertension associated with congenital heart disease followed-up at 
six different German centres (133). The current study confirms these results 
and expands on these findings by providing a detailed overview over the 
time-course of improvement in objective exercise capacity during long term 
follow-up. 
Eisenmenger syndrome and pulmonary arterial hypertension associated with 
congenital heart disease are associated with right ventricular hypertrophy 
and subsequent right ventricular dysfunction. Endothelin antagonism may 
attenuate these adaptive right ventricular changes by reducing right 
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ventricular afterload. Indeed, ECG derived voltage criteria for right ventricular 
hypertrophy inn proved compared to baseline. This is consistent with 
experimental data demonstrating attenuated right ventricular hypertrophy 
after treatment with endothelin antagonists in various animal models of 
pulmonary hypertension (131,136). However, patients with Eisenmenger 
physiology represent a unique and heterogeneous patient group. Especially 
in patients with non-restrictive ventricular communication the right ventricle is 
not only exposed to elevated pulmonary arterial pressures but also to 
systemic pressures. Therefore, further studies incorporating comprehensive 
imaging techniques are required to elucidate whether endothelin antagonism 
may indeed have the potential to reverse long-standing right ventricular 
hypertrophy in these patients. 
3.6. Limitations 
This was a descriptive and retrospective study in which the presence of 
confounding elements and a placebo effect cannot be excluded. 
Nevertheless, previous studies in patients with pulmonary arterial 
hypertension have consistently demonstrated that improvements in six 
minute walk test distance were not observed beyond the first 12 weeks of 
therapy (46,47), indicating that the early improvement in the six minute walk 
test as seen in the current study is due to a genuine treatment effect of 
Bosentan. No invasive haemodynamic data is available as serial cardiac 
catheterization in this setting provides limited information and maybe 
associated with considerable risks for the patient. Further studies, including a 
larger number of patients and robust imaging modalities such as cardiac 
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magnetic resonance imaging are required to assess the potential of 
endothelin antagonism to induce right ventricular remodeling in patients with 
pulmonary arterial hypertension associated with congenital heart disease. 
3.7. Conclusion 
The vast majority of Eisenmenger patients have limited exercise capacity. 
There is a four-fold increase in mortality amongst contemporary adult 
patients with Eisenmenger syndrome followed up in a tertiary specialized 
centre. Poor functional class, clinical and laboratory signs of heart failure and 
a history of arrhythmias were all predictive of death. These data may be 
helpful in guiding clinicians and assisting targeting therapies in patients with 
Eisenmenger physiology. Bosentan - a competitive endothelin receptor 
antagonist - appears to be safe and well tolerated in adults with pulmonary 
arterial hypertension associated with congenital heart disease or 
Eisenmenger syndrome during mid to long-term follow-up. In addition 
functional class and the six-minute walk test distance improved and this 
effect was maintained up to 2 years of Bosentan therapy. 
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Chapter IV Cyanosis and Impaired Tissue Oxygen 
Delivery 
4.1. Background of the study 
Shunt lesions are common in adult congenital heart disease (ACHD) patients 
and affect exercise capacity in this population. Not surprisingly, right-to-left 
shunting with cyanosis was found to be an important determinant of oxygen 
consumption in ACHD patients (1). Right-to-left shunting reduces arterial 
oxygen content thereby impairing oxygen delivery to tissue. In physiologic 
terms, reduced arterial oxygen content decreases arterio-venous oxygen 
difference thus impairing peak oxygen consumption according to the Pick 
principle (21) as illustrated in Equation 4.1: 
VO2 = CO • A av02 Equation 4.1 
VO2 = oxygen consumption; CO = cardiac output; • A av02 = arterio-venous O2 difference 
To quantify the amount of oxygen available to tissue the concept of oxygen 
delivery has been developed (Equation 4.2) (137): 
Oxygen delivery = cardiac output x arterial O2 content Equation 4.2 
This concept combines systemic blood flow, oxygen carrying capacity and 
oxygen saturation into a single parameter by multiplying them together (137). 
Increasing any of these parameters will invariably increase their product. 
Therefore it is widely used in quantifying oxygenation status for example in 
the intensive care unit (138). However, in situations where increases in 
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systemic flow are achieved at the expense of decreases in systemic oxygen 
saturation - such as in patients with shunt lesions (e.g. bidirectional 
cavopulmonary shunt and univentricular circulation) - this simple approach of 
multiplying flow and arterial saturation can easily be misleading. In principle 
venous parameters of oxygenation may be better suited to characterise 
tissue oxygenation in this setting. Venous blood has returned from tissues 
with which it has recently been in equilibrium; its oxygen saturation offers 
useful information about tissue oxygenation not available from arterial 
parameters (139). 
In this series of studies equations defining the mandatory relationship 
between physiologic variables and oxygen delivery were formulated in 
patients with right-to-left shunting and fixed pulmonary blood flow as well as 
patients with bidirectional cavopulmonary shunt and univentricular 
circulation. Using calculus and computer modeling the effects of blood flow 
distribution, different metabolic rates, oxygen-carrying capacity and 
pulmonary blood flow on oxygen delivery and markers of tissue oxygenation 
were considered. 
4.2. Oxygen Delivery in Patients with Bidirectional Cavopulmonary 
Shunt and Univentricular Circulation 
The bidirectional cavopulmonary shunt is used in the staged palliation of 
patients with univentricular circulation. As illustrated in Figure 4.1. in this 
circulation pulmonary blood flow is supplied exclusively by venous return 
from the upper body via the superior vena cava. This represents an 
inherently inefficient circulation uncoupling lower body perfusion from 
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pulmonary blood flow. This study aimed to explore the complex relationship 
between systemic blood flow, arterial and venous oxygen content and tissue 
oxygenation in patients with a bidirectional cavopulmonary shunt. 
4.2.1. Methods 
A standard model of the univentricular circulation after the bidirectional 
cavopulmonary anastomosis was used, as shown in Figure 4.1. and 
explained in the legend. 
Cardiac output is represented by CO. This is considered to have two 
components, Qsvc and Qivc, with coronary sinus flow considered, to be part 
of inferior vena cava flow. Cao2 represents the oxygen carrying capacity of 
blood. A steady state is assumed. When blood flowing at Q l/min gaining 
oxygen at a rate of V l/min while passing through an organ (e.g. the lungs), 
its oxygen concentration must rise by V/Q. Its saturation, being the ratio 
between oxygen content and carrying capacity Capo2, must therefore rise by 
(V/Q)/Capo2 • This (Pick) principle applies to all locations where oxygen is 
transferred. Across the lung bed, 
S s v c o g = SPVOG - V02/(QSVC • CAPOG) Equation 4.3 
Across the upper part of the systemic circulation, 
Sao2 = SSVC02 + kV02/(Qsvc • Capog) Equation 4.4 
= Spvog + (k-1 )V02/(QSVC • Capoz ) 
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Across the lower part of the systemic circulation, 
SivCq2= Sao2 - (1-k)V02/(Qivc • Capog) Equation 4.5 
= Spvo2 — ((1"k)V02/Capo2) 1 1 ^ + 
v "iisvc Qivc 
Mathematical analysis 
The ultimate aim is to maximise tissue oxygen tension. An increase in 
cardiac output, a decrease in total body metabolism, or an increase in 
oxygen carrying capacity would clearly increase oxygen tension. However, 
the effect on oxygenation of changes in metabolic balance between upper 
and lower parts of the body, and changes in blood flow to these two parts, is 
less obvious. 
Differential calculus provides simple and well-validated methods for 
analysing the behaviour of such complex systems of equations without a 
computer. Differential calculus was applied to the formulae above, to study 
the effect of changes in the proportion of metabolism occurring in the upper 
body (k) and changes in the proportion of blood flow to the upper body 
(Qsvo/CO) on total oxygen delivery to the systemic circulation, and on 
saturation in the systemic arteries and superior and inferior vena cava. 
The effect on the conventional parameters of oxygen status (140): total 
oxygen delivery, upper-body oxygen delivery, lower-body oxygen delivery, 
and the oxygen saturations Sa02, Ssvco2 and Sivco2 was examined. Of 
these, the last two may best represent tissue oxygen status, since they refer 
to blood that has been in equilibrium with tissues. However, choosing 
between them is not straightforward. Ssvco2 is the lower of the two in some 
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circumstances, and Sivco2 in others. Therefore a novel parameter Sminoz, 
which we defined as the lower of these two values was considered. 
Graphical display 
As an alternative method of displaying the results to the symbolic 
mathematics, a computer was used to generate graphs showing the effect of 
changes in metabolic and flow balance on oxygen status. Computer 
calculations are not as general as the analytical approach because specific 
values must be chosen. For the purpose of this study 0.2 l/kg/min for cardiac 
output and 0.009 l/kg/min for oxygen consumption, which are suitable 
approximations for the post-surgical situation in neonates (140,141) were 
used. Oxygen carrying capacity of blood was taken as 0.207 I O2/I blood, 
based on conventional values (140) of 1.38'10-3 1 O2 per gram haemoglobin, 
and a haemoglobin concentration of 150 g/l. Pulmonary venous saturation 
was taken as 98% (142). It should be remembered that these specific values 
were used only in order to obtain specific oxygen saturations for the 
purposes of graph plotting. The conclusions derived from the calculus 
analysis apply, in contrast, to all possible values of these four variables. 
4.2.2. Results 
Effect of changes in metabolic and flow balance on arterial parameters 
The four conventional arterial parameters of oxygenation are SaOa, total 
oxygen delivery (CO • Cap02 • SaOs) (140) and its two components upper 
body oxygen delivery and lower body oxygen delivery. Since total oxygen 
delivery is Sa02 multiplied by a constant factor (CO • Cap02), studying the 
119 
effect on Sa02 is sufficient to determine the effect of flow distribution and 
metabolic balance on total oxygen delivery. 
Inspection of equation 4.4 reveals that Sa02 is a linear function of (k-1 )/Qsvc. 
As k is always <1, a rise in k or a rise in Qsvc always causes a rise In SaOa. 
For any given distribution of metabolism (k), Sa02 is therefore maximal when 
Qsvc is maximal (Figure 4.2). Therefore complete diversion of all the blood 
through the upper part of the body, with none to the lower part, achieves the 
greatest SaOz (and thus the greatest total oxygen delivery). 
Upper body oxygen delivery (Qsvc • Cap02 • Sa02) equals, by application of 
equation 4.4, Qsvc * Cap02 • SpvOa - (1-k) O2. This expression increases 
linearly with Qsvc and with k, and so again for any k, it is maximal when Qsvc 
is maximal (see Figure 4.4), i.e. when all the flow goes to the upper body, 
and no blood to the lower. 
Lower body oxygen delivery (Qivc • Cap02 • Sa02) equals, by application of 
equation 4.4, (CO - Qsvc)' Cap02 • SpvOa - (1 k) O2 • (CO/Qsvc - 1). 
Applying calculus, the derivative of this expression with respect to Qsvc is (1-
k) O2 • CO/Qsvc^ - Cap02 • Spv02. For maximal lower body oxygen 
delivery, this derivative must be zero, i.e. the proportion of blood flowing to 
the upper body is: 
Qsvc^ Equation 4.6 
CO ^COCapo^Spvo^ 
The dependence of lower body oxygen delivery on the distribution of flow 
and metabolism is shown in Figure 4.4. The highest achievable lower-body 
oxygen delivery (for a given k) is marked with a dot. These dots form a 
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parabola, which corresponds to equation 4.6. As k increases, the Qs/CO 
fraction required falls, until it reaches zero when k=1. 
Effect of changes in metabolic and flow balance on venous parameters 
There are two conventional venous oxygenation parameters: Ssvco2 and 
S1VC02. Ssvco2 represents blood that has recently been in equilibrium with the 
tissues of the upper part of the body: its value therefore gives useful 
information about tissue oxygenation in that region. Equation 4.3 shows that 
Ssvco2 is independent of k, and increases with increasing Qsvc- It is therefore 
maximal when all the blood flows through the upper body (see Figure 4.3), 
regardless of any other physiological variables. 
S1VC02 represents blood that has recently been in equilibrium with the tissues 
of the lower body: its value therefore provides information about lower-body 
tissue oxygenation. From equation 4.5, we can see that Sivcoz is a non-linear 
function of k and blood flow distribution, whose maximum point may not be 
obvious by inspection. By calculus, its first derivative with respect to Qsvc is 
( 1 - k ) 
V, o. ' 1 1 ' 
Capo, 
Equation 4.7 
.Qsvc ' Qivc 
For S1VC02 to be maximal, this derivative must be zero; this occurs when Qsvc 
= QIVC, i.e. half the flow passes to each part of the circulation. Again, this is 
true for any value of k and of the other parameters (see Figure 4.3). 
Since Ssvco2 and Sivco2 peak at different flow balances, the question might 
arise: which of them is more important? Both are important, and that in any 
scenario the lower of the two values represents the greater degree of tissue 
hypoxia. Therefore a parameter Smin02 was defined which takes the value 
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of Ssvco2 when Ssvco2 < Sivco2, and of Sivco2 when S|vco2 - Ssvco2- From 
equations 4.3 and 4.5, it can be seen that the former situation occurs when 
Vo, c 1 \ 
Capo i^Qsvc 
1 
> (l - k ) - ^ — + —-— Equation 4.8 ^ 1 1 ^ 
Capo, Qsvc Qivc 
I.e. 
^>(l-k)5svc±5lvc Equation 4.9 
Qsvc Qsvc • QIVC 
or > ( l - k ) , which means Qsvo/CO > k. In other words, where the 
fraction of blood perfusing the upper body is less than the fraction of 
metabolism occurring in the upper body, Smin02 is Ssvcoz, otherwise it is 
S|VC02-
Thus the situations are markedly different depending on whether k is above 
or below 0.5. For k<0.5, Smin02 is maximised when flow is equally 
distributed to the upper and lower parts of the body, while for k>0.5, Smin02 
is maximised by distributing flow in proportion to metabolism (Figure 4.4). 
4.3. Atrial RIght-to-Left Shunting in Pulmonary Arterial Hypertension 
and its Effect on Tissue Oxygenation and Systemic Blood Flow 
Atrial right-to-left shunting occurs in patients with an atrial septal defect and 
pulmonary hypertension (e.g. Eisenmenger syndrome) and it has been 
argued that the interatrial communication may function as a "pop-off' valve, 
allowing to decompress the right ventricle and to maintain systemic blood 
flow when metabolic demand is increased (143), for example during exercise 
and pulmonary arterial hypertensive crises, albeit at the expense of cyanosis 
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(144). In addition, the artificial creation of an "atrial septal defect" - i.e. 
balloon atrial septostomy - has been proposed as a therapy option for highly 
symptomatic patients with pulmonary arterial hypertension refractory to 
advanced vasodilator therapy (145-147). The artificially created, atrial 
septostomy has been shown to improve haemodynamics and quality of life 
and prolong survival (145,148-152). 
It is not clear whether the benefits from atrial right-to-left shunting in the 
setting of pulmonary arterial hypertension arise entirely from increased blood 
flow (i.e. preservation of an adequate perfusion pressure), or whether 
improved oxygen transport contributes. There is no doubt that systemic 
blood flow increases and arterial oxygen saturation falls after atrial 
septostomy. It is unclear whether the increase in blood flow is adequate to 
compensate for the decrease in oxygen saturation: it is therefore not known 
whether tissue oxygen status improves, stays the same, or deteriorates. 
Clinical studies have observed an increase in calculated arterial oxygen 
delivery (145), and this is currently widely accepted as evidence of improved 
tissue oxygen status (145,150,153). However, oxygen delivery is potentially 
flawed in patients with abnormal circulatory connections. 
Therefore a modeling study into the effect of right-to-left shunting on useful 
oxygen delivery, mixed venous oxygen content and systemic cardiac output 
in patients with pulmonary arterial hypertension and fixed pulmonary blood 
flow was performed. 
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4.3.1. Methods 
A standard model of the circulation in the presence of a right to left shunt on 
atrial level was used, as shown in Figure 4.5 and explained in the legend. 
In the presence of a right-to-left shunt systemic blood flow (Qs) represents 
the sum of pulmonary blood flow (Qp) and right-to-left shunt volume (QRL). A S 
a consequence of admixture of venous blood bypassing the lungs to 
pulmonary venous blood, arterial oxygen content (Caoa) is the weighted 
mean of mixed venous oxygen content and pulmonary venous oxygen 
content:: 
(.^^2 = CkNCK ' Qw + Cpvo2-G, f5qL,8f/on 4.70 
QRL + Qp 
Ca02 = arterial oxygen content; CMvo2=fTiixed venous oxygen content; Cpvo2 = pulmonary 
venous oxygen content; Qp = pulmonary blood flow; Q r l = right to left shunt. 
Mixed venous oxygen saturation represents the difference between arterial 
oxygen content and the amount of oxygen removed at tissue level: 
VOz 
CMVO2 = CAOG : — Equation 4.11 
Qs 
CMvo2=mixed venous oxygen content; Cpvo2 = pulmonary venous oxygen content; Qp = 
pulmonary blood flow; VO2 = total body oxygen consumption 
By combining the equations for Ca02 and C m v o 2 given above systemic 
venous oxygen content (C1VIV02) can equally be expressed as: 
C m v o 2 — Cpvog Equation 4.12 
Gp 
Arterial oxygen Ca02 content was calculated by combining Equation 4.10 and 
4.11 to eliminate Civivo2 from the equation and solving for Ca02 as follows: 
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1. Ca02 (QrL+QP) c 
*^PV01 QRL + Cpv02 • Q p 
2 . CA02 ( Q r l + Q P ) - CPVO2 ' QRL — — " Q r l + CpV02 " Q p 
3 . CA02 (QRL+QP ) - CPVO2" (QRL + Q p ) — — ' QRL 
after dividing by ( Q R L + Q P ) : 
4. Ca02 - CpV02 — 
gp (Q«i + Gp) Equation 4.13 K/'/ y 
Ca02 = arterial oxygen content; Cpvoz = pulmonary venous oxygen content; Qp = pulmonary 
blood flow; Q r l = right to left shunt; VO2 = total body oxygen consumption 
Oxygen content represents the product between oxygen saturation, 
haemoglobin concentration and oxygen carrying capacity of blood (K= 1.38 x 
10"^  L of O2 per gram of haemoglobin) (140). 
Therefore, arterial oxygen saturation can be calculated by dividing Equation 
4.13 by (k- haemoglobin concentration): 
Sata02 - Satpvo2 - Q^i • YO2 
K-Hb-Qp- (Q^i + Qp) 
Equation 4.14 
Sata02 = arterial oxygen saturation; Satpvo2 = pulmonary venous oxygen saturation; Qp = pulmonary 
blood flow; Q r l = right to left shunt; Hb = haemoglobin concentration; • = oxygen carrying capacity of 
blood; VO2 = total body oxygen consumption 
To illustrate the effect of changes in distribution of pulmonary blood flow, 
total body oxygen consumption and left ventricular output on arterial and 
systemic mixed venous oxygen content, a computer model was developed 
using commercial mathematical modeling software (Matlab 6.5, Mathworks, 
USA and R version 2.6.1, R Foundation for Statistical Computing, Vienna, 
Austria). If not otherwise stated oxygen carrying capacity of blood was taken 
125 
as 0.207 I O2/I blood, based on conventional values of 1.38-10'^ L O2 per 
gram haemoglobin, and a haemoglobin concentration of 150 g/l (140). 
4.3.2. Results 
Effect of Changes in Right-to-Left Shunting and Pulmonary Blood Flow on 
Arterial Oxygen Saturation 
The impact of different combinations of pulmonary blood flow and right-to-left 
shunting on arterial oxygen saturations was examined. For any given 
combination of pulmonary blood flow and VO2, arterial oxygen saturation 
decreases with increasing degree of right-to-left shunting as illustrated in 
Figure 4.6. Figure 4.6B also demonstrates that for low values of pulmonary 
blood flow even small increases in shunt volume drastically reduce arterial 
oxygen saturation, whereas at higher levels of pulmonary blood flow arterial 
oxygen saturations are relatively independent of changes in shunt volume. 
Impact of Changes in Right-to-Left Shunt Volume on Hemodyanamic 
Parameters and Arterial Oxygen Delivery 
The effects of varying right-to-left shunt fractions on systemic cardiac output, 
arterial blood pressure, arterial oxygen saturation and oxygen delivery in the 
presence of fixed pulmonary blood flow were studied. As systemic blood flow 
represents the sum of pulmonary blood flow and right-to-left shunt volume 
any increase in shunt volume will lead to a linear increase in systemic 
cardiac output. If total systemic vascular resistance remains constant, arterial 
blood pressure (representing the product between systemic blood flow and 
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systemic vascular resistance) will increase in proportion to increased 
systemic blood flow. 
Exploring the relationship between shunt volume and arterial oxygen delivery 
reveals that arterial oxygen delivery (Daoz) increases in a linear fashion with 
increasing degree of right-to-left shunting {Equation 4.15): 
= (Cpvoz — ) • QRL + Qp • Cpvog; as (Cpvog — ) = CMVO2 this 
Qp 
Y 
is identical to 
Dugj = ( C1VIV02 • QRL ) + ( QP • CPVOG ) 
Dao2 = arterial oxygen delivery; Cpvo2 = pulmonary venous oxygen content; Qp = pulmonary blood 
flow; Q r l = right to left shunt; VO2 = total body oxygen consumption; = identical to 
The relationship between right-to-left shunt volume and arterial oxygen 
content is illustrated in Figure 4.7. 
Impact of Changes in Right-to-Left Shunt Volume on mixed venous oxygen 
content 
This modeling study indicates that in contrast to arterial oxygen delivery 
mixed venous oxygen content (which mirrors tissue oxygen tension) is 
independent of the degree of right-to-left shunting and therefore is unaffected 
by an increased shunt fraction (as demonstrated by Equation 4.12 and 
illustrated in Figure 4.7). 
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Impact of right ventricular dysfunction on oxygen status 
Adequate right ventricular function is critical in maintaining pulmonary blood 
flow. If the right ventricle is unable to increase its output to match pulmonary 
blood flow then this in itself can become the limiting factor to oxygenation. As 
shown in Figure 4.8 any reduction in right ventricular output impairs arterial 
oxygen delivery and mixed venous oxygen saturation. 
Lower limit of pulmonary blood flow for any given oxygen consumption and 
oxygen carrying capacity 
To maintain adequate tissue oxygenation a minimal pulmonary blood flow is 
required for any given combination of oxygen consumption, oxygen carrying 
capacity and the ability of peripheral organs to extract oxygen. As illustrated 
in Equation 4.16, minimal required pulmonary blood flow (Qpumit) is 
independent of the degree of right-to-left shunting. In fact, the minimal 
required pulmonary blood flow is determined by the ratio between oxygen 
consumption, the product of haemoglobin concentration, K (=1.38 • 10-3 L of 
O2 per gram of haemoglobin) and the difference between pulmonary venous 
saturation and the minimal mixed venous oxygen saturation achievable 
(SatMvo2min)- Reducing oxygen consumption, augmenting the ability of tissue 
to utilize oxygen (i.e. reducing SatMvo2min) and increasing haemoglobin 
concentration will reduce minimal required pulmonary blood flow. 
VO, 
SatMvo2min = minimal mixed venous saturation; Satpvo2 = pulmonary venous oxygen saturation; Qp = 
pulmonary blood flow; Hb = haemoglobin concentration; k = oxygen carrying capacity of blood; VO2 = 
total body oxygen consumption 
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Impact of Haemoglobin Concentration on Arterial Oxygen Delivery and 
Tissue Oxygen Status 
Exploring the relationship between haemoglobin concentration and arterial 
oxygen delivery reveals that arterial oxygen delivery (Daoz) increases in a 
linear fashion with increasing haemoglobin concentration (Hb). Re-arranging 
Equation 4.15 and replacing Cpvo2 by SatpvOa • k • Hb yields: 
QRL VO; 
Da02 = [(SATPV02 • K • (QRL + QP)] - Hb Equation 4.17 
Gp 
Dao2 = arterial oxygen delivery; Satpvo2 = pulmonary venous oxygen saturation; Qp = pulmonary blood 
flow/; Q r l = right to left shunt; VO2 = total body oxygen consumption; Hb = haemoglobin concentration; 
K = oxygen carrying capacity of blood 
Therefore, for any given combination of pulmonary venous oxygen saturation 
(Satpvoz), oxygen carrying capacity (K) and systemic blood flow (QP+QRL) , 
arterial oxygen content increases in proportion to haemoglobin concentration 
with a slope of [(SatpvOa • k • (QRL + Qp)]. 
In addition, mixed venous oxygen concentration increases with increasing 
haemoglobin concentration: 
VO, 
SatMvo2 = Satpvop Equation 4.18 
K-Hb-Qp 
Satwvoa = mixed venous saturation; Satpvo2 = pulmonary venous oxygen saturation; Qp = pulmonary 
blood flow; Hb = haemoglobin concentration; K = oxygen carrying capacity of blood; VO2 = total body 
oxygen consumption 
As a consequence decreases in Qp can be offset by a proportional increase 
in haemoglobin concentration {Equation 4.18) as shown in Figure 4.9: 
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4.4. Figures 
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VO2 is the total body oxygen consumption. Systemic organs of the upper part of the body 
consume a proportion k of this (k VO2), and their blood flow Qsvc drains into the superior 
vena cava (SVC) whose oxygen saturation is Sgvcoz- Organs of the lower part of the body 
are responsible for the remainder, (1-k) VO2, of the body's oxygen consumption and their 
blood flow Qivc drains into the inferior vena cava (IVC) whose saturation is Sivco2- SaOa and 
Spv02 represent the saturations in systemic arteries and pulmonary veins respectively. 
Figure 4.1: Model of the circulation in patients with functionally univentricular 
hearts with a bidirectional cavopulmonary anastomosis shown as a cartoon 
(upper panel) and as a mathematical schematic (lower panel)
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Figure 4.2: Effects of changes in metabolic and flow balance on arterial 
parameters: a) arterial saturation; b) upper-body oxygen delivery; c) lower 
body oxygen delivery 
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Figure 4.3: Effects of changes in metabolic and flow balance on venous 
oxygenation parameters; a) superior vena cava saturation; b) inferior vena 
cava saturation; c) So2min, defined as the lower of these two. 
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Figure 4.4: Difference between two strategies for optimising tissue 
oxygenation with a cardiac output of 0.2 1/kg/min (middle panels) and with a 
cardiac output of 0.3 1/kg/min (lower panels). In each panel, the lower curve 
represents the effect of a distribution of blood flow in proportion to oxygen 
uptake in the upper and lower body; the straight lines represent the effect of 
maintaining equal flows to upper and lower body whenever k<0.5. 
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LA = left atrium, LV = left ventricle; Op = pulmonary blood flow; Q r l = right to left shunt; Qs = 
systemic blood flow; VO2 = total body oxygen consumption. 
Figure 4.5: Model of the circulation in the presence of a right to left shunt on 
atrial level. 
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Figure 4.6: A) Arterial oxygen saturation (%) as a function of right-to-left 
shunt (QRL) for a given total body oxygen consumption (taken as 300 ml/min 
for this example) and different values of pulmonary blood flow (QP). B) 
Arterial oxygen saturation for different combinations of pulmonary blood and 
right-to-left shunt. The arrows demonstrate that the same increase in right-to-
left shunting causes a bigger decrement in oxygen saturations when 
pulmonary blood flow is lower. 
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Figure 4.7: Arterial oxygen saturation, arterial oxygen delivery and mixed 
systemic venous oxygen saturation as a function of right-to-left shunt for a 
given total body oxygen consumption (taken as 300 ml/min in this example) 
and different values of pulmonary blood flow. Note that despite a drop in 
arterial oxygen saturation, arterial oxygen delivery is augmented and mixed 
venous oxygen content is unaffected as right-to-left shunt increases. RV = 
right ventricle. 
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Figure 4.8: Effect of right ventricular output on oxygenation response. 
Arterial oxygen saturation (black), arterial oxygen delivery (red) and systemic 
venous oxygen saturation (blue) as a function of right ventricular output for a 
given total body oxygen consumption (taken as 300 ml/min in this example) 
and different values of right-to-left shunt volume. If the right ventricle is 
unable to increase its output to match pulmonary blood flow then this in itself 
can become the limiting factor to oxygenation: In the figures above, to the 
right of the arrows it is the pulmonary blood flow that is limiting, and to the left 
of the arrow it is right ventricular output that is limiting oxygen status. 
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Figure 4.9: Effect of haemoglobin concentration on mixed venous oxygen 
saturation. A reduction (from 4 L/min to 2 L/min in this example [segment 
AB]) in pulmonary blood flow Is offset by a proportional increase in 
haemoglobin concentration (from 10 g/dL to 20 g/dL in this example 
[segment BC]). 
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4.5. Discussion 
Oxygen delivery to tissue represents a complex and poorly understood 
phenomenon in various forms of congenital heart disease such as patients 
with univentricular circulation or shunt lesions. This is due to multiple 
interacting parameters affecting oxygen transport in this setting. Therefore, 
simple intuition cannot determine the effect that a change in one 
physiological measure will have on another. Mathematical models provide a 
way of assessing the independent effect of individual parameters. A 
mathematical model is a simplified abstract view of the complex reality. Such 
models are typically used when it is impractical to create experimental 
conditions to measure outcomes directly. As no adequate animal models of 
complex cyanotic heart disease exist and it is unethical to subject patients 
with these conditions to potentially dangerous interventions to manipulate 
and measure parameters of oxygen transport, we contend that mathematical 
modeling represents an ideal way to study the complex pathophysiologic 
changes underlying impaired oxygen delivery and ultimately exercise 
intolerance in this cohort. 
The bidirectional cavopulmonary anastomosis represents a modification of 
the classical Glenn shunt introduced 50 years ago and is commonly used in 
the staged palliation of patients with univentricular circulation (154). In this 
circulation pulmonary blood flow is supplied exclusively by venous return 
from the upper body via the superior vena cava. Both the classical and the 
bidirectional cavopulmonary shunt improve systemic arterial oxygen 
saturation by augmenting the effective pulmonary blood flow without 
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increasing total pulmonary blood flow and without volume loading the 
ventricle (155). The bidirectional cavopulmonary anastomosis was chosen 
for this modeling study because it is at the extreme end of the spectrum of 
"unphysiologic" circulatory connections and represents an inherently 
inefficient circulation uncoupling lower body perfusion from pulmonary blood 
flow. 
This study examined the effect of the bidirectional cavopulmonary 
anastomosis on oxygenation using a quantitative model of the circulation and 
oxygen saturation. It developed the known relationships between 
physiological variables into equations suitable for analytical solution by 
differential calculus, which allowed consideration of all conditions of cardiac 
output, metabolic rate, oxygen carrying capacity and pulmonary venous 
saturation simultaneously. 
The main findings of this study are; (1) conventional arterial parameters 
(arterial oxygen saturation, total oxygen delivery, upper and lower body 
oxygen deliveries) are poor markers of tissue oxygenation in these patients; 
(2) venous saturation, which represents tissue oxygenation most closely, 
differs between the upper and lower body. Since neither is consistently lower 
than the other, a parameter SminOz can be defined as the lower of the two, 
representing the degree of hypoxia in whichever part of the body is more 
hypoxic; (3) when the majority of the metabolism Is in the upper body, 
SminOa is maximised when the flow distribution matches the metabolic 
distribution (and the two venous saturations are equal). In contrast, when the 
majority of the metabolism is occurring in the lower part of the body, SminOa 
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is optimised by an equal distribution of blood flow between the upper and 
lower body regardless of the exact ratio of metabolic rates. 
Difficulties with arteriai parameters of oxygenation 
Arterial parameters are an initially attractive choice in attempting to quantify 
oxygenation. Due to its ease of measurement arterial oxygen saturation is 
commonly used in clinical settings, but it gives at best an incomplete picture. 
It peaks when all the blood is diverted to the upper body, and the lower body 
is starved of oxygen, which is not a clinically desirable outcome. Total 
oxygen delivery to systemic tissues has also been considered as a variable 
to be maximised, yet for any given cardiac output, it is simply proportional to 
arterial saturation, and so this choice would also favour a complete diversion 
of blood to the upper body, regardless of the status of the lower body. 
Choosing one of the two parts of the systemic circulation individually offers 
no advantage: maximising upper body oxygen delivery would require 
diverting all the blood to the upper body; maximising lower body oxygen 
delivery, although plausible at low values of k, would require diverting almost 
all the blood to the lower body at higher values of k, which represent 
relatively less metabolism in the lower body. Since the two partial-body 
oxygen delivery parameters favour discordant and clinically unsuitable flow 
distributions, no oxygen delivery parameter is suitable for maximisation in 
seeking to optimise tissue oxygenation in a circulation with a cavopulmonary 
anastomosis. 
Previous considerations of the functionally univentricular circulation (156) 
and its partially corrected states (140) have concentrated on oxygen delivery 
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as a useful parameter to be maximised. Francis et al. questioned this 
principle in this setting (156), since oxygen delivery takes no account of the 
quality of oxygen at the point of its transfer into tissues: it implicitly assumes 
that a halving of arterial oxygen saturation can be fully compensated for by a 
doubling of flow, a clinically unacceptable assumption. 
Lessons from venous parameters of oxygenation 
Venous blood has returned from tissues with which it has recently been in 
equilibrium: its oxygen content offers useful information about tissue 
oxygenation not available from arterial parameters. This study shows that 
upper and lower body venous saturations (and therefore tissue oxygenation 
states) are different. Neither is always lower, and thus neither can be used in 
Isolation as a summary of tissue oxygenation. This modeling study suggests 
that attention should be concentrated on whichever of these two parts of the 
systemic circulation is suffering the greater hypoxia. The variable Smin02 
was constructed to reflect this. 
A key finding of this modeling study is that in situations when the lower body 
is responsible for the majority of the oxygen consumption, an equal 
distribution of flow between upper and lower body optimises SminOg. In 
contrast, when the majority of metabolism is in the upper body, a distribution 
of flow in proportion to metabolic rate is preferable. 
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Does matching oxygen delivery to oxygen consumption optimise 
oxygenation? 
Although maximisation of oxygen delivery may be unwise, a possible 
alternative would be to distribute flow in proportion to the balance of oxygen 
uptake. Previous theoretical work has proposed this to be optimal (in the 
situation where k=0.6) (140). The results of the current study support this 
choice, but observes that it is valid only as long as k remains in excess of 
0.5. 
For values of k below 0.5, our study indicates that such a choice would 
cause unnecessarily poor oxygenation in both upper and lower circulations. 
Figure 4.4 illustrates the difference between a strategy of matching oxygen 
delivery to consumption (which equalises SVC and IVC saturation, shown as 
circles and crosses superimposed) and a modified strategy of holding the 
flow balance constant at 50:50 when k falls below 0.5 (resulting in different 
oxygen saturations in SVC (circles) and IVC (crosses)). There is a clear 
difference in the tissue oxygenation achieved which is even larger when 
cardiac output is higher (0.3 l/kg/min, shown in Figure 4.4. 
Oxygen delivery or tissue oxygenation? 
The concept of oxygen delivery was originally advanced in high risk adult 
surgical patients without congenital heart disease as a means of combining 
into a single parameter cardiac output, oxygen carrying capacity and oxygen 
saturation (simply by multiplying them together). Since increasing any one of 
them increases their product, and would intuitively be expected to be 
beneficial, oxygen delivery is attractive as a summary of overall oxygenation 
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(137). Survivors were found to have higher oxygen deliveries than non-
survivors which has led to the hypothesis that elevating oxygen delivery to 
supranormal levels may confer survival benefit. Although randomised 
controlled trials results of this intervention have had conflicting results 
(138,157) a consensus seems to have developed that when oxygen delivery 
is low, interventions to raise it may be worthwhile, while in those with normal 
oxygen deliveries, the benefits of elevating it supranormally are less 
convincing (158,159). 
In congenital heart disease with a single functioning ventricle, however, there 
can be an unavoidable trade-off between blood flow and arterial oxygen 
saturation. This means that it becomes important how the summary 
parameter values the relative merits of flow and saturation: oxygen delivery 
considers them to be interchangeable. In such circumstances, therefore, 
oxygen delivery can be a seriously misleading measure of oxygenation 
(156). 
Impact of bidirectional cavopulmonary anastomosis on exercise capacity 
The bidirectional cavopulmonary anastomosis is inherently inefficient, and 
becomes increasingly so with growth and maturation. Growth is associated 
with a relative increase in blood flow to the lower body. While in newborns 
the superior vena caval flow accounts for approx. 50% of the cardiac output, 
its contribution diminishes to 35% by the age of 6 years (160). During 
exercise lower body blood flow increases further (due to increased oxygen 
and metabolic demand). This requires augmented cardiac output and 
imposes additional strain on the univentricular heart. Maintaining an optimal 
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ratio between upper and lower body perfusion is - in theory - an alternative 
and may be most important in patients with limited cardiac output reserve. 
However, this may not be possible during exercise due to local tissue factors 
(such as lactate and acidosis) leading to local vasodilation and a 
disproportionate increase in lower body blood flow. Ultimately, therefore, the 
Glenn circulation becomes inadequate, and increasingly places limits on the 
level of exercise that can be achieved. 
The only practical solution is definitive surgical completion of the Fontan 
circulation. These theoretical results are confirmed by previous studies 
showing that growth and maturation are inversely correlated with arterial 
oxygen saturation in this setting (161). 
With a right-to-left shunt deoxygenated systemic venous blood returns 
directly to the systemic arterial circulation. The oxygen content of the 
systemic arterial blood is reduced in proportion to the volume of systemic 
venous blood mixing with the normal pulmonary venous return. With reduced 
oxygen content, even if cardiac output is normal, tissue oxygen delivery falls 
and the work capacity of the muscles is limited (162). 
Studying patients with right-to-left shunt in the setting of fixed pulmonary 
blood flow this modelling study suggests that inducing right-to-left shunting in 
patients with fixed pulmonary blood flow (for example by creation of an atrial 
septostomy) increases raw systemic oxygen delivery for any given value of 
pulmonary blood flow. However, this is revealed to be an artefact of the way 
raw oxygen delivery is defined, which may not be appropriate for patients 
145 
with shunt lesions. In fact, mixed systemic oxygen saturation - arguably the 
most important index of tissue oxygenation - is not improved by right-to-left 
shunt on atrial level In this setting. These findings eliminate the possibility 
that globally improved oxygenation is a significant benefit of atrial 
septostomy. Rather, this study suggests that the clinical improvement 
reported in patients undergoing atrial septostomy must have another 
explanation, for example the greater leeway for flow redistribution available 
because of the increased systemic flow. In addition, our model suggests why 
patients with impaired ventricular function may be less able to derive clinical 
benefits from atrial septostomy. 
Clinical studies have shown that atrial septostomy is safe and effective in 
patients with idiopathic pulmonary hypertension (145,146,151). It has been 
reported that syncope is abolished, functional class improves and right heart 
failure ameliorates in many patients. Furthermore, by transferring blood from 
right to left in patients with severe pulmonary hypertension it has the 
potential to attenuate right ventricular volume overload and improve left 
ventricular filling leading to improved biventricular function (146,150). 
But beyond the immediate hemodynamic effect, whether oxygenation is 
improved is a difficult question to answer by qualitative reasoning alone. It is 
said that "oxygen transport to the tissues improves due to an increase in 
cardiac output, despite a modest reduction in systemic arterial oxygen 
saturation." as a result of atrial septostomy (146). This study does agree that 
atrial septostomy augments raw arterial oxygen delivery. However, the effect 
of simultaneously increasing systemic blood flow and reducing arterial 
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oxygen saturation on arterial oxygen delivery is not intuitively obvious and 
depends on the balance between these two factors. This study shows, that 
increased oxygen delivery does not coincide with improved tissue 
oxygenation in this setting. In fact, average tissue oxygenation (as quantified 
by venous oxygen status) is found to be entirely unaffected by the addition of 
the intracardiac shunt and in fact it is determined only by the ratio between 
total oxygen consumption and pulmonary blood flow. 
One possible explanation for this is that therapeutic right-to-left shunting is 
effectively permitting blood that has recently left contact with body tissues to 
simply return for a second contact with body tissues. Unless there had been 
insufficient time for equilibrium to take place on the first visit, the second visit 
will, on average not result in any significant further transfer of blood gases. 
Since blood flow is only very rarely so fast that oxygen does not have time to 
equilibrate, and patients with this physiology are in fact at the opposite end of 
the blood flow velocity spectrum, it is very likely that the second circulation of 
blood in these patients does not assist oxygen transport. 
It appears likely that the source of the clear clinical benefits of atrial 
septostomy must therefore lie elsewhere. Despite not improving tissue 
oxygenation, atrial septostomy augments systemic blood flow, potentially 
benefiting organs that lack the ability to autoregulate blood flow at low blood 
pressures. It has been reported that a mean arterial pressure of at least 60 
mmHg is required to enable cerebral autoregulation (163). Interestingly, atrial 
septostomy has been demonstrated to be especially effective in abolishing 
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syncope. Atrial septostomy could protect against syncope by maintaining 
systemic cardiac output, particulariy when the pulmonary arterial pressure 
rises acutely (146). In the situation of desperately poor systemic blood flow, 
autoregulation may not be able to successfully maintain flow to some vital 
territories - an increase in total flow could permit autoregulatory processes to 
restore perfusion to vital organs, even if the overall average tissue oxygen 
status is no better. 
Clinical Implications 
The concept of oxygen delivery is useful in patients without congenital heart 
disease as a simple means of combining cardiac output, oxygen carrying 
capacity and oxygen saturation into a single parameter (137). In patients with 
shunt lesions, however, there can be an unavoidable trade-off between blood 
flow and arterial oxygen saturation. In such circumstances, therefore, oxygen 
delivery can be a seriously misleading measure of oxygenation(156,164) and 
should be avoided. 
Atrial septostomy does not improve average tissue oxygen status as defined 
by venous oxygenation. Rather, this study suggests that tissue oxygen status 
can be improved by increasing pulmonary blood flow (using advanced 
medical therapies), limiting maximal oxygen consumption (for example by 
discouraging extreme exertion), and improving blood oxygen carrying 
capacity (by maintaining adequate haemoglobin concentrations and avoiding 
iron-deficient anaemia in cyanotic patients) (28,165). This model also 
suggests that a critical pulmonary blood flow exists below which adequate 
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tissue oxygenation cannot be acliieved. The exact value of this metabolically 
critical pulmonary blood flow depends on oxygen consumption, blood oxygen 
carrying capacity and the ability of tissue to extract oxygen - again 
emphasizing the need of adequate haemoglobin concentrations in these 
patients. Metabolically, critical pulmonary blood is found to be independent of 
right-to-left shunt volume. 
The current study cannot evaluate the relationship between size of the 
interatrial communication and right-to-left shunt volume. In fact, this 
association is complex and confounded by numerous dynamic physiologic 
processes such as atrial wall distensibility, relative resistance to filling of the 
right and left ventricle, heart rate, and systemic venous return (166,167). The 
study suggests, however, that the empirically determined size of the 
interatrial communication is more critical in patients with low pulmonary blood 
flow. In these patients a small increase in right-to-left shunt volume will cause 
a greater decrement in arterial oxygen saturation compared to patients with 
higher values of pulmonary blood flow. 
Right ventricular function is critical in maintaining adequate pulmonary blood 
flow. It has been reported that atrial septostomy attenuates right ventricular 
volume overload and has the potential to improve right ventricular function 
(150). If however despite atrial septostomy right ventricular function 
continues to deteriorate pulmonary blood flow decreases and tissue oxygen 
status worsens. As illustrated in Figure 4.7 mixed venous oxygen content is 
independent of shunt volume, therefore increased right-to-left shunting 
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cannot compensate for right ventricular failure in this setting. Our modeling 
study, therefore, emphasizes the importance of adequate biventricular 
function in patients with pulmonary arterial hypertension considered for atrial 
septostomy. 
4.6. Conclusion 
Investigating two "unphysiologic" circulatory conditions unique to patients 
with congenital heart disease these modelling studies shed light on the 
effects of blow flow distribution, right-to-left shunting and pulmonary 
perfusion on oxygen uptake and ultimately exercise capacity in patients with 
bidirectional cavopulmonary anastomosis or right-to-left shunt on atrial level 
and pulmonary hypertension. It was revealed that oxygen delivery (total, 
upper body or lower body) is not a suitable parameter to maximise in patients 
a bidirectional cavopulmonary anastomosis. Even matching oxygen delivery 
distribution to the oxygen consumption of the upper and lower body does not 
(in general) optimise tissue oxygenation. Because there is a trade-off 
between flow distribution and saturation, it is unwise to concentrate on 
maximizing oxygen delivery. Maximizing systemic venous saturations is 
conceptually different and physiologically preferable for tissue oxygenation. 
However, this study also revealed that the bidirectional cavopulmonary 
anastomosis is inherently inefficient and cannot be "optimized" in a real life 
scenario. It limits exercise tolerance by uncoupling oxygen consumption from 
oxygen uptake and by inducing cyanosis, thereby reducing arterio-venous 
oxygen difference. The only practical solution to improve exercise capacity in 
150 
this situation is definitive surgical completion of the Fontan circulation. 
Similarly, oxygen delivery was found to an inadequate parameter to describe 
tissue oxygen status in patients with atrial right-to-left shunt and fixed 
pulmonary blood flow. Interatrial shunting was revealed to have no effect on 
tissue oxygen status in this setting. Therefore, from a theoretical point of 
view, exercise capacity cannot be improved by creating a right-to-left shunt in 
patients with pulmonary hypertension. Rather, this study emphasizes the 
importance of adequate pulmonary blood flow and blood oxygen carrying 
capacity in maintaining tissue oxygenation thereby improving exercise 
capacity. 
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Chapter V Inflammation and Endothelial 
Progenitor Cells 
5.1. Background of the study 
Endothelial dysfunction is ubiquitous in patients with heart failure and adults 
with congenital heart disease and relates to exercise intolerance and 
symptoms (57-60). Recently endothelial dysfunction has been linked to 
reduced availability of vasoactive mediators, the presence of inflammation 
and reduced number of bone marrow derived endothelial progenitor cells 
(EPCs) (69). This study aimed to test the hypothesis that patients with 
congenital heart disease have reduced number and impaired function of 
EPCs, altered concentrations of vasoactive mediators, increased levels of 
asymmetric dimethylarginine (ADMA) and evidence of inflammation. This 
study focused on adult patients with Eisenmenger syndrome (pulmonary 
hypertension and cyanosis in the presence of congenital heart disease) 
known to have the worst exercise capacity among ACHD patients. Healthy 
individuals and patients with idiopathic pulmonary hypertension (IPAH) were 
included as control subjects. 
5.2. Methods 
Study Subjects 
Subjects were recruited from the Adult Congenital Heart Centre and Centre 
for Pulmonary Hypertension, Royal Brompton Hospital and the Hammersmith 
Hospital, London between July 2006 and December 2007. Approval from the 
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local ethics committees was obtained, and all study subjects provided written 
informed consent. 
Flow Cytometric Detection of Circuiating Endothelial Progenitor Cells 
Peripheral blood mononuclear cells (PBMNCs) were isolated by density 
centrifugation using Vacutainers CRT cell preparation tubes (BD 
Biosciences) or Ficoll-Paque (GE Healthcare Life Sciences, Little Chalfont, 
UK), according to the manufacturer's instructions. Endothelial progenitor 
cells were enumerated, using established criteria, as CD34+ cells co-
expressing AC133 and VEGF receptor-2 (VEGFR2/fetal liver kinase 1/KDR) 
or cells co-expressing CD34 and KDR (168,169). 10® PBMCs were 
incubated with FITC-labeled monoclonal mouse anti-human CD34 (BD 
Biosciences, Oxford, UK), PE-labeled monoclonal mouse anti-human AC 133 
(Miltenyi Biotec, Surrey, UK) and allophycocyanin-labeled monoclonal mouse 
anti-human KDR (R&D Systems, Abingdon, UK) antibody for 30 min at 4°C, 
according to the manufacturers' instructions. In parallel experiments, 
appropriate isotype controls were used and at least 100,000 events acquired 
in the lymphomonocytic gate using a FACSCalibur cytometer (Becton 
Dickinson, Oxford, UK). The number of progenitor cells was expressed as a 
percentage of all lymphomonocytic cells. 
Case and colleagues reported that PBMNCs co-expressing 
CD34+AC133+KDR+ may represent primitive hematopoietic progenitors and 
may not relate to colony-forming unit endothelial cells (170). In contrast, 
CD34+cells not expressing the common leukocyte antigen (CD45) were 
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found to yield colony-forming units endothelial cells in their study. We 
therefore quantified endothelial progenitor cells as lymphomonocytic cells 
expressing CD34 with low expression of CD45 (PE labeled monoclonal 
mouse anti-human CD45, BD Biosciences, Oxford, UK) as CD45lowCD34+-
EPCs in accordance to previous studies (171,172). Furthermore, to account 
for the possibility of different levels of lymphomonocytic cells in the different 
subject groups, EPC levels were corrected for the number of 
lymphomonocytic cells and compared to the percentages of EPCs in the 
lymphomonocytic gate. 
Enumeration of Colony Forming Units (CFU) 
In addition to direct evaluation of circulating EPCs, the colony forming 
capacity and angiogenic potential of cells derived from PBMNCs in culture 
were assessed as these have been reported to correlate with systemic 
vascular endothelial dysfunction and prognosis in other cardiovascular 
diseases (173,174). Colony forming units were obtained from PBMNCs 
plated (5x10® PBMNCs/well) on fibronectin-coated six-well plates (BD 
Biosciences) in EndoCult™ medium (StemCell Technologies, London, UK) 
according to the manufacturer's instructions. After 48 h, non-adherent cells 
were collected and re-plated (1x10® cells/well) in duplicate in fibronectin-
coated 24-well plates. Colonies were counted three days later by two 
investigators in a blinded fashion. Colonies were defined as a central core of 
"round" cells with radiating "spindle-like" cells at the periphery and referred to 
as early outgrowth CFU-endothelial cells (also referred to as CPU-Hill 
colonies)(173). 
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Staining of Cultured Cells and Incorporation into Tube-Like Structures 
Isolated PBMNCs (10^ cells/well) were cultured in fibronectin-coated six well 
plates in endothelial-basal medium-2 (EBM2) supplemented with EGM 
SingleQuots (Cambrex Bio Science Ltd., Wol<ingham, UK) for 7 days. 
Adherent cells were identified, as previously described (175,176), by uptake 
of 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate-labelled 
acetylated low-density lipoprotein (5 pg/ml Dil-Ac-LDL for 1 hr at 37°C: 
Serotec Ltd., Kidlington, Oxford, UK.); binding of fluorescein isothiocyanate 
(FITC)-conjugated Ulex europeus agglutinin (10 pg/ml UEA-1 for 1 hrat 
37°C; Sigma-Aldrich Co., Ltd., Gillingham, UK); and immunostaining for Von 
Willebrand factor (vWf), using a polyclonal rabbit anti-human vWf antibody 
(A0082; DakoCytomation Ltd., Ely, UK). After washing, cells were stained 
with Hoechst 33342 nuclear dye (0.5 pmol/L for 1 hr at room temperature) 
and observed by fluorescence microscopy. Adherent cells were trypsinized 
after 7 days in culture and the number derived from the 10^ PBMNCs 
originally plated was quantified using a haemocytometer. 
The angiogenic potential of cultured mononuclear cells was defined by the 
number of cells incorporated in to endothelial tube-like structures, as 
previously described (177). Briefly, adherent cells were labeled with 
Vybrant® CFDA SE cell tracer (Invitrogen, Paisley, UK) after 7 days in 
culture. Following treatment with trypsin, cells (5 x 10^ cells/well) were mixed 
with human umbilical vein endothelial cells (2 x 10"^  cells/well) in 300 pi of 
EBM-2 medium with EGM SingleQuots and incubated in eight-well chamber 
glass slides (Lab-Tek™) pre-coated with 200 pi Matrigel (BD Bioscience, 
Oxford, UK). After eight hours of incubation in a 5% COz humidified 
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atmosphere at 37°C, cells were examined by fluorescence microscopy. The 
number of labelled cells incorporated into endothelial tubes was determined 
in three randomly selected fields per well, by at least two investigators in a 
blinded fashion. 
Detection of Circulating Inflammatory Mediators, Asymmetric 
Dimethylarginine, Nitric Oxide Metabolites, cGMP and Brain Natriuretic 
Peptide 
Blood, obtained at the same time as the sample for PBMNC isolation, was 
drawn from the antecubital vein, collected in EDTA and citrate tubes and 
placed immediately on ice. Following centrifugation, plasma samples were 
stored at -80°C until further analysis. Levels of the chemokine (C-C motif) 
ligand-2 (CCL)-2 (formerly monocyte chemotactic protein-1, Quantikine® 
immunoassay DCPOO, sensitivity < 5.0 pg/mL, R&D Systems, Abingdon, 
UK): tumour necrosis factor-a (TNF-q Quantikine® HS immunoassay 
HSTAOOD, mean minimum detectable dose 0.106 pg/mL, R&D Systems): 
interlukin-6 (IL-6, Quantikine® HS immunoassay HS600B, mean minimum 
detectable dose 0.039 pg/mL, R&D Systems); vascular endothelial growth 
factor (VEGF, (QuantiGlo® immunoassay DVEOO, sensitivity < 9 pg/mL, 
R&D Systems, Abingdon, UK): cGMP (Enzyme-immunoassay Biotrak® 
System RPN226, sensitivity 161 pg/ml, GE Healthcare, Little Chalfont, UK); 
C-reactive protein (CRP, Quantikine® immunoassay DCRPOO, mean 
minimum detectable dose 0.010 ng/mL, R&D Systems) and ADMA (DLD 
Diagnostica, Hamburg, Germany), were quantified using commercial ELISA 
assays according to the manufacturer's instructions. 
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The combined concentrations (NOx) of plasma nitrite (NO2") and nitrate 
(NO3"), the stable oxidation products of nitric oxide (NO), were determined 
using a NO chemiluminescence detector (NOA 280, Sievers), as described 
previously (178). Plasma samples were deproteinated by centrifugation in 
3KDa MW cut-off filter units (Uitracel Microcon YM-3). In addition, a full blood 
count, renal function tests and brain-type natriuretic peptide (BNP) levels 
were obtained. 
Statistical Analysis 
Data are expressed as mean ± standard deviation (SD) or median and 
interquartile range (IQR). Statistical analysis was performed with the non-
parametric Mann-Whitney U test and Spearman correlation, using R version 
2.4.1. (179) and MedCalc 8.1 (MedCalc Software, Mariakerke, Belgium). 
Regression analyses were performed after variables were log-transformed to 
achieve normal distribution. For all analyses, a 2-sided P-value of less than 
0.05 was considered statistically significant. 
5.3. Results 
Subjects 
Fifty-five patients with idiopathic PAH (44 female, age 46+14 years), 41 
Eisenmenger patients (27 female, age 37+12 years, 13 with Down 
syndrome) and 47 healthy controls (24 female, age 36+9 years) were 
recruited. To account for differences in gender distribution between the 
different subject groups, EPC numbers were examined separately in male 
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and female subjects. The Eisenmenger population was younger than the 
IPAH cohort and patients exhibited secondary erythrocytosis, with raised 
haematocrit and haemoglobin levels as well as cyanosis (Table 5.1). 
Endothelial Progenitor Numbers 
Circulating EPC numbers, as defined by the number of double-
(CD34+/KDR+) or triple-labeled cells (CD34'^/AC133^/KDR^) cells, were 
significantly lower in patients with Eisenmenger syndrome and IPAH (Figure 
5.1) in, both, the female and the male population. Within the Eisenmenger 
population, patients with Down syndrome had the lowest number of 
circulating EPCs irrespective of gender. Progenitor cell numbers, defined as 
single (CD34^) or double-labeled cells (CD34^/AC133^) were also lower in 
the Eisenmenger population compared to control and IPAH subjects whereas 
the two latter groups had similar levels of progenitor cells (Figure 5.1). 
Stratifying subjects by decades of age revealed that differences in EPC 
numbers between patients and controls were maintained throughout all age 
groups. No significant difference in the lymphomonocyte cell counts were 
found between controls, Eisenmenger and IPAH subjects as shown in Table 
5.1. Consistent with this observation, correcting EPC numbers (expressed as 
a % of lymphomonocytes) for actual lymphomonocyte cell counts in 
individual patients did not affect the results of the study. In addition, 
CD45'°^CD34^-cells were significantly lower in non-Down Eisenmenger 
syndrome patients (0.377 vs. 1.073 %; P = 0.003) and Down-Eisenmenger 
syndrome patients (0.430 vs. 1.073; P = 0.02) compared to control subjects. 
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Levels of CD45'°^CD34^-cells were not significantly different between 
controls and idiopathic PAH subjects. 
Association between Endothelial Progenitor Numbers and Exercise 
Tolerance 
Within the Eisenmenger population there was an inverse relationship 
between circulating EPC numbers and exercise tolerance as judged by 
NYHA functional class and six minute walk distance. EPC numbers were 
significantly higher in Eisenmenger patients in NYHA functional class 2 
compared to those in NYHA class 3, as determined by the number of single-
(CD34+: median 0.099 vs. 0.062, P =0.03), double- (CD34^/AC133^: median 
0.032 vs. 0.013, P =0.009; CD34+KDR+: median 0.029 vs. 0.012, P=0.02) or 
triple-labeled cells (CD34^/AC133WEGFR2^: median 0.007 vs. 0.002, P 
=0.008). The number of progenitor cells also correlated directly with six-
minute walk test distance in the Eisenmenger population (r=0.64, P =0.008), 
as shown in Figure 5.2. 
In contrast, no significant difference was found in the EPC numbers in IPAH 
patients assigned to NYHA class 2, 3 and 4. 
Association between Treatment for PAH and Endothelial Progenitor 
Numbers 
IPAH patients receiving treatment with the phosphodiesterase type 5 (PDE5) 
inhibitor sildenafil exhibited significantly higher circulating EPC levels than 
patients not receiving sildenafil (Figure 5.3). Furthermore, there was a dose-
dependent relationship between sildenafil exposure and circulating EPC 
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numbers, irrespective of the surface labels used to identify the cells (Figure 
5.3). In contrast, no such difference in EPC numbers was found in IPAH 
patients treated with bosentan or other targeted therapies compared to 
treatment naive patients and control subjects (Figure 5.3). Similarly, no 
significant difference was found in the number of progenitor cells in 
Eisenmenger patients treated with bosentan compared to treatment naive 
patients (data not shown). Eleven IPAH patients were also taking a 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (atorvastatin, 20 
mg od, n=1: simvastatin, 40-80 mg od, n=10). The circulating EPC numbers 
in this cohort did not differ significantly from controls, but they were 
nonetheless excluded from the analyses of patients receiving sildenafil. 
Colony Forming Units-Endothelial Cells and Adherent Cells 
Characteristic CFU-endothelial cells were observed following culture of 
PBMNCs in Endocult™ medium for 5 days (Figure 5.4). Consistent with the 
flow cytometric analysis of circulating progenitors, significantly fewer colony 
forming units were obtained with PBMNCs isolated from patients with 
Eisenmenger syndrome, compared to controls, whereas there was a trend 
towards increased numbers of colonies in patients with IPAH (Figure 5.4). No 
significant difference was found in the colony forming capacity of 
Eisenmenger patients with and without Down syndrome (Figure 5.4). 
Similarly, patients with Eisenmenger syndrome had significantly lower 
numbers of adherent cells derived from PBMNCs after 7 days in culture 
compared to control in IPAH subjects. In contrast, IPAH patients had 
160 
significantly higher numbers of adherent cells compared to control subjects 
(Figure 5.5). 
Incorporation of Cultured Cells into Tube-Like Structures 
After 7 days in culture, all adherent cells exhibited Vybrant® CFDA SE cell 
tracer labeling, Dil-Ac-LDL uptake and immunostaining for vWf and a major 
proportion also displayed UEA-1 binding (Figure 5.5). Cells derived from 
patients with Eisenmenger syndrome had a reduced capacity to incorporate 
into tube-like structures with human umbilical vein endothelial cells (median 
14.8 cells/field [IQR 11.5-40.7]; n= 5) compared to cells derived from normal 
controls (51.3 cells/field [IQR 42.7-59.3]; n= 8 ; P = 0.028) and patients with 
I PAH (60.3 cells/field [IQR 44.5-71.0]; n= 8 ; P = 0.019), as illustrated in 
Figure 5.5. In contrast no significant difference was found between control 
subjects and patients with I PAH. 
Circulating Inflammatory Mediators and Indices of Endothelial Dysfunction 
The plasma levels of inflammatory mediators were significantly higher in 
Eisenmenger and I PAH patients compared to control subjects and, within the 
Eisenmenger population, patients with Down syndrome had higher levels of 
TNF-a, IL-6, CCL-2 and CRP compared to non-Down Eisenmenger patients 
(Figure 5.6). Levels of inflammatory mediators correlated with each other and 
the white blood cell count (WBC) (r-values between 0.25 - 0.62, for TNF-a 
vs IL-6, CRP and WBC, as shown in Figure 5.7. Furthermore, in the 
Eisenmenger population the concentration of TNF- a and CRP also 
correlated with combined plasma NQ-2 and NO-3 levels (Figure 5.7). 
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Plasma ADMA levels were significantly higher in patients with Eisenmenger 
syndrome and I PAH, compared to healthy control subjects (Figure 5.6). 
Within the Eisenmenger population, those with Down syndrome had 
significantly higher ADMA levels (median 1.23 pmol/l [IQR 0.90-1.69]) 
compared to patients without Down syndrome (median 0.82 fimol/l [IQR 
0.72-0.89]; F=0.009). Circulating levels of cGMP and NO metabolites were 
also both significantly elevated in patients with Eisenmenger syndrome or 
I PAH compared to control subjects, with markedly higher levels occurring in 
patients with Down syndrome (Figure 5.6). Plasma NOx levels comprised 
mainly NOs", with no differences observed in the levels of NO2" among the 
groups. While no direct correlation was found between cGMP-levels and 
NOx levels, BNP and cGMP levels were positively associated in patients with 
Eisenmenger syndrome (r=0.74 , P =0.0001), as shown in Figure 5.8. 
In contrast to the elevated cytokines, plasma VEGF levels were significantly 
lower in Eisenmenger patients compared to control subjects and IPAH 
patients, with no significant difference between Down and non-Down 
Eisenmenger patients (Figure 5.6). 
Association between circulating EPC Numbers and Infiammatory Mediators, 
ADMA, BNP and cGMP 
Overall, the number of circulating CD34^KDR^- EPCs was negatively 
correlated with levels of TNF-a, IL-6 and GRP and raised levels of ADMA 
were also associated with lower EPC numbers (Figure 5.7). A bimodal 
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relationship was found between cGMP levels and numbers of circulating 
ERCs. When subjects were stratified according to diagnosis a positive 
association was observed between cGMP levels and circulating EPC 
numbers in control subjects and to a lesser degree in I PAH patients (Figure 
5.9). In contrast, a significant negative association was found between cGMP 
levels and circulating EPCs in Eisenmenger patients (Figure 5.9), who on 
average had the highest cGMP levels (Figure 5.6). In addition, BNP levels 
and circulating EPC numbers were also inversely correlated in the 
Eisenmenger population (Figure 5.8). Furthermore, a significant inverse 
correlation between BNP levels and plasma cGMP levels was found 
potentially confounding the relationship between plasma cGMP levels and 
EPC numbers in the Eisenmenger population. 
Association between circulating EPC Numbers, cGMP ieveis and 
haemodynamic parameters 
Higher circulating EPC numbers and cGMP levels were found to be 
associated with significantly lower mean pulmonary arterial pressures and 
higher cardiac index in patients with IPAH (Figure 5.10). 
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5.4. Tables 
Eisenmenger 
(N = 41) 
IPAH 
(N=55) 
Control 
subjects 
(N=47) 
Age (years) 37+12 t 46+14* 36±9 
Male/female 14/27 11 /44* 24 /23 
Diabetic patients (%) 0 4 -
NYHA class 2 / 3 / 4 ( % ) 4 9 / 5 1 / 0 4 2 / 5 4 / 4 -
6MWT distance (m) 303+81 t 362+110 -
Arterial SpCb rest (%) 83+71 93+6 -
Time since diagnosis (years) 22.3+10.71 3.6+2.8 -
Medication 
Warfarin 15 % t 87% -
CCBs 3 % 9 % -
Digitalis 8 % 24% -
Diuretics 3 0 % t 52% -
Statins 5 % 20% -
ACE-lnhibitors 14% 7% -
Organic nitrates 5% 0% -
Bosentan 23 % t 56% 
Sildenafil 3 % t 45% -
Prostacyclin analogues 3 % t 28% -
Double therapy ^ 3 % t 35% -
Triple therapy ^ 0% 4 % -
Treatment naive 74% 11 % 
Hemodynamic Parameters ^ 
Mean PAP (mmHg) - 57+12 -
Systolic PA pressure (mmHg) 103+20t 87+22 -
PVR dyne • s • cm-® - 1034+478 -
Cardiac Index (L/min/m^) - 2.32+0.95 -
Laboratory parameters 
Hemoglobin (g/dl) 20.1+2.6 * t 15.0+2.3 14.6+1.3 
Hematocrit (%) 61.7±8.3*t 42.4+11.3 42.3+13.6 
White blood cell count (10^/1) 7.2±2.4 * 7.9+2.1 * 5.5+1.8 
Lymphocyte count (10^/1) 1.8+0.6 1.9+0.8 1.7+0.4 
Monocyte count (1041) 0.6+0.2 0.6+0.2 0.6+0.4 
Lymphomonocyte count (10®/L) 2.4+0.6 2.5+0.9 2.3+0.7 
^ Double and triple therapy, refers to combined use of endothelin receptor antagonists 
(bosentan or sitaxsentan), phosphodiesterase type 5 inhibitors (sildenafil) and prostacyclin 
analogues (epoprostenol or treprostinil). Mann-Whitney U tests and tests were used for 
comparison as appropriate. *P<0.05 versus control subjects; t P<0.05 versus I PAH patients. 
6 M W T distance, six-minute walk test distance; ACE-lnhibitors, angiotensin converting 
enzyme inhibitors; CCB, calcium channel blockers; I PAH, idiopathic pulmonary arterial 
hypertension; NYHA, New York Heart Association functional class; PVR, pulmonary 
vascular resistance; SpOa transcutaneous resting arterial oxygen saturation (%); PAP, 
pulmonary arterial pressure. 
Table 5.1: Patients' characteristics 
5.5. Figures 
164 
E^MALESUBJECTS-AfxeOtn 
COM' coawcw 
tt*i£su0JKns 
fi 
C0»WC1]»W 
i j • ' J ; « • ; j 'OY: iSQ 
0 000 ' 0 00 J • » « 000 • 
coaww C0)tAC:334W 
Figure 5.1: Circulating progenitor cells in female and male subjects. 
Proportion of CD34\ CD34VAC133^ , CD34VKDR'" and CD34+/AC133+/ 
KDR"" labeled cells, expressed as a percentage of lymphomonocytic cells, in 
controls and patients with Eisenmenger syndrome (EM) with and without 
Down syndrome or idiopathic pulmonary hypertension (IPAH). *, P< 0.05 
versus controls; t , P < 0.05 versus IPAH patients. 
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Figure 5.2: Correlation between progenitor cell numbers and six minute walk 
test distance in Eisenmenger patients without Down syndrome. 
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Figure 5.3: Relationship between sildenafil treatment and circulating 
progenitor cells. A, Comparison between circulating CD34VAC133'' cells in 
controls and IPAH patients treated with sildenafil, bosentan or prostacyclin 
analogues. B-C, Dose-dependent correlation between sildenafil therapy and 
CD34^VAC133'^ or CD34^/KDR^cell numbers, compared to treatment naive 
patients and controls. 
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Figure 5.4; Colony forming units-endothelial cells. A, Examples of typiical 
colony forming units. B, Comparison between control subjects, Eisenmeiniger 
and IPAH patients. C, Comparison between Down and non-Down sybjecte 
within the Eisenmenger population. 
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Figure 5.5: A) Number of adherent cells from control, Eisenmenger and 
IPAH subjects and number of cells incorporated in to HUVEC tube-like 
structures. B) Adherent cells, after 7 days culture displaying (arrows) Dil-Ac-
LDL uptake, FITC-UEA-1 labeling and Hoechst counterstained nuclei; C) 
Incorporation of Vybrant-labeled cells (green fluorescence) in to HUVEC 
tube-like structures. *, P < 0.05 versus controls; +, P < 0.05 versus IPAH 
patients. 
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Figure 5.6; A) Plasma levels of tumor necrosis factor-a (TNF-a), interleukin-
6 (IL-6), monocyte chemotactic protein-1 (MCP-1/CCL-2) and C-reactive 
protein (CRP). B) Plasma levels of asymmetrical dimethylarginine (ADMA), 
cyclic GMP (cGMP), total plasma nitrate/nitrite levels (NOx") and vascular 
endothelial growth factor (VEGF) in control, Eisenmenger (EM) with and 
without Down syndrome and IPAH subjects. *, P < 0.05 versus controls; +, P 
< 0.05 versus IPAH patients. 
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Figure 5.7: Correlation between inflammatory mediators (tumor necrosis 
factor-a [TNF-a], interleukin-6 [IL-6] and C-reactive protein [CRP]) or 
asymmetrical dimethylarginine (ADMA) and numbers of circulating 
CD34VKDR'' cells. Regression analyses performed after log-transformation. 
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Figure 5.8: Correlation between brain-type natriuretic peptide (BNP) and 
cyclic GMP (cGMP) levels, CD34\ CD34^-AC133^ or CD34^-AC133^-KDR^ 
progenitor cells in patients with Eisenmenger syndrome. 
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Figure 5.9: Relationship between plasma cGMP levels and circulating 
CD34^KDR^ ERCs in control, Eisenmenger and IPAH subjects. Overall, 
locally weighted regression analysis indicates a bimodal relationship. 
Stratification into cohorts reveals positive association between cGMP levels 
and EPC numbers in control and IPAH subjects and a negative association 
in Eisenmenger subjects. Histograms with overlaid density estimates 
illustrate the higher levels of cGMP in Eisenmenger subjects compared to 
control and IPAH subjects (see also Figure 5B). 
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Figure 5.10; Correlation between haemodynamic parameters (mean 
pulmonary arterial pressure [PAP] or cardiac index) and cGMP levels or 
circulating CD34^/KDR'^ cells in patients with I PAH. Parameters were log-
transformed. 
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Figure 5.11: Interplay between immune inflammation, oxidative stress (t free 
radicals), reduced nitric oxide (NO)-bioavailability and endothelial progenitor 
cell (EPC) numbers and function, endothelial dysfunction and ultimately 
exercise intolerance. 
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5.6. Discussion 
Endothelial dysfunction has been reported in adult patients with congenital 
heart disease and pulmonary hypertension and may be associated with 
exercise intolerance in this group of patients (70). Recently, it has been 
suggested that endothelial progenitor cells (EPCs) derived from the bone 
marrow have a role in ongoing endothelial repair and that impaired 
mobilization or depletion of these cells may contribute to endothelial 
dysfunction and peripheral vascular disease (173,180). The number and 
function of EPCs are altered in atherosclerosis, in high-risk individuals for 
cardiovascular events, in patients with stable and unstable angina, and after 
myocardial infarction (173,180-182). In addition, immune inflammation is 
prevalent in adult congenital heart disease and is linked to endothelial 
dysfunction and thereby reduced exercise capacity (80,183). The complex 
interplay between immune inflammation, oxidative stress, reduced nitric 
oxide bioavailability and EPC numbers and function is illustrated in Figure 
5.11. 
This study assessed the number of circulating EPCs and function of cultured 
mononuclear cells in patients with Eisenmenger syndrome and idiopathic 
pulmonary arterial hypertension (IPAH). The major findings were that the 
number of circulating EPCs (CD34"^/KDR"' or CD34"'/AC133VKDR^) was 
markedly reduced in patients with Eisenmenger syndrome or IPAH. This 
reduction was most profound in Eisenmenger patients with Down syndrome. 
The reduction in circulating EPCs was associated with reduced functional 
capacity of cultured PBMNCs in patients with Eisenmenger syndrome, but 
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not in patients with I PAH. Elevated levels of inflammatory mediators, indices 
of nitric oxide synthesis and ADMA were found in PAH patients and 
correlated directly with EPC numbers. In Eisenmenger patients, there was a 
close correlation between plasma levels of BNP and cGMP and BNP related 
inversely to EPC numbers in this cohort. Notably, EPC numbers were also 
related to pulmonary haemodynamic parameters in IPAH patients and 
chronic sildenafil treatment was associated with dose-dependent elevation of 
circulating EPC numbers in this cohort. 
Both Eisenmenger syndrome and IPAH are associated with pulmonary and 
systemic vascular endothelial dysfunction (57,59,184). In the present study, 
the reduction in EPC numbers in Eisenmenger patients showed a correlation 
with disease severity, as measured by functional class and six minute walk 
distance, and numbers were lowest in patients with Down syndrome. As a 
subgroup, Eisenmenger patients with Down syndrome have particularly poor 
survival prospects (185) and show more rapid progression of symptomatic 
pulmonary vascular disease than other patients with Eisenmenger syndrome 
(30). These findings are in accordance with observations in various 
cardiovascular cohorts, suggesting that low EPC numbers are associated 
with a worse prognosis (169,173,174). Patients with IPAH also exhibited 
significantly fewer circulating EPCs compared with healthy controls and the 
number of cells correlated directly with cardiac index. In addition, there was a 
trend towards lower EPC numbers in IPAH patients with higher mean 
pulmonary arterial pressures, although this association was potentially 
confounded by the effect of sildenafil treatment. It is also possible that 
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mechanistic differences (e.g. involving chronic cyanosis, erythrocytosis, 
increased blood viscosity and associated shear stress) between 
Eisenmenger and I PAH patients have diverse effects on the number of 
circulating cells and function of cultured cells. 
The mobilization and function of EPCs is thought to be critically dependent 
on nitric oxide (NO) (186). In the current study plasma concentration of 
ADMA was raised in both Eisenmenger and IPAH patients, which is in 
keeping with previous studies (187),(188). Although increased ADMA levels 
are associated with reduced NO bioavailability, elevated systemic levels of 
stable NO oxidation products were found in this study, which is consistent 
with earlier reports of raised nitrate levels in adults as well as children with 
congenital heart disease (189). A positive correlation was found between 
cGMP levels and EPC numbers in control subjects and IPAH patients, yet 
despite high NOx and cGMP plasma concentrations, circulating EPCs were 
not only deficient in Eisenmenger patients but also exhibited a negative 
association with plasma cGMP levels. There are several potential 
explanations for this phenomenon, but NO and the natriuretic peptides are 
the major factors stimulating cGMP synthesis in pulmonary vascular tissue 
(190). In experimental animals, increased pulmonary blood flow and 
associated pulmonary hypertension is accompanied by raised circulating 
levels of BNP and cGMP (191) .The levels of these two factors were also 
closely correlated in patients with Eisenmenger syndrome, potentially 
obscuring any direct association between NO and cGMP production. 
Increased circulating inflammatory mediators also accompanied raised 
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plasma NOx levels and cytokine inducible NO synthase expression has been 
described in pulmonary arteries and cardiac tissues of patients with flow-
associated pulmonary hypertension and cyanotic congenital heart disease 
(192,193). This represents a potentially important source of "high-output" 
NO production that may be associated with oxidative stress and the 
production of reactive NO species that attenuate the mobilization, function 
and survival of EPCs (194,195). 
Increasing evidence indicates that inflammation has a key role in the 
pathogenesis of PAH. As in earlier studies (196-198), evidence of chronic 
inflammation with raised plasma levels of the inflammatory mediators TNF-
a^.lL-6 and CCL-2 was found. Increased pulmonary production of CCL-2 in 
PAH is postulated to act as a chemoattractant for circulating monocytes 
(198), whereas both TNF- a and IL-6 have a negative effect on the number 
and function of EPCs (169,199,200). We also found that plasma CRP was 
elevated and, together with the inflammatory cytokines, negatively 
associated with the number of circulating EPCs. In this regard, CRP has 
been found to attenuate endothelial NO synthase (eNOS) expression and the 
mobilization, differentiation and survival of EPCs (201,202). 
An important finding of this study was that IPAH patients treated with the 
PDE5 inhibitor sildenafil exhibited a selective and dose-dependent increase 
in circulating EPCs. Studies of erectile dysfunction have indicated that acute 
and chronic PDE5 inhibition, with vardenafil and tadalafil respectively, is 
associated with increased circulating CD34VAC133'' progenitor cells 
179 
(203,204). This study, however, is the first report of the effects of a PDE5 
inhibitor on EPC numbers in patients with PAH. Given that eNOS is 
expressed in cultured EPCs (205) and NO released from organic nitrates can 
augment circulating EPCs (186,194), it is possible that, unlike other targeted 
therapies for PAH, sildenafil stimulates an intrinsic NO-cGMP pathway, 
thereby augmenting EPC numbers. It is unclear whether the effect of 
sildenafil confers a therapeutic advantage, but there is active interest in using 
bone marrow-derived cells to treat IPAH (206-208). Data obtained from 
experimental models suggest that these cells may induce regeneration of 
pulmonary perfusion, leading to improved hemodynamics and survival 
(206,208). Furthermore, Wang et al., recently found that the intravenous 
infusion of cultured autologous cells in IPAH patients was associated with an 
augmented six-minute walk test distance and pulmonary haemodynamics 12 
weeks later (209). Nonetheless, there remain a number of unanswered 
questions with this therapeutic approach and a simpler alternative strategy 
may be the pharmacological manipulation of EPCs in vivo. 
In this study circulating progenitor cells were characterised using a variety of 
surface markers (168,169), (170), (171,172). Adherent PBMNCs, following 
short term culture, have been widely studied and previously also classified as 
EPCs, but are now considered to be mainly of monocyte origin (210). 
Despite their distinct phenotypes (170), the colony forming capacity and in 
vitro function of cultured PBMNCs has been related to endothelial 
dysfunction, cardiovascular symptoms and outcome (173,211). In the 
present study, in vitro analysis of PBMNCs revealed differences between 
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patients similar to those of circulating CD34VAC133'' cells. Thus, while the 
number and in vitro function of cells from IPAH patients was similar or even 
greater than controls both were severely impaired in Eisenmenger patients. 
It is uncertain whether therapeutic intervention in PAH patients influences 
cultured as well as circulating cells, but components of the NO-cGMP 
pathway are present in PBIVINCs (205),(212) and PDE5 inhibition for erectile 
dysfunction associated with augmented function of cultured cells (213). 
Several cytokines and growth factors are implicated in the mobilization and 
homing of EPCs. While levels of inflammatory mediators and ADMA were 
elevated in both forms of PAH studied, levels of the angioenic protein VEGF 
were selectively reduced in Eisenmenger patients. VEGF is a potent stimulus 
for mobilizing bone marrow-derived EPCs (214) and lower levels may be 
important in this patient group. Indeed, it may be interesting to investigate 
whether there is an imbalance between other angiogenic (e.g. IL-8) and anti-
angiogenic factors (e.g. endostatin) in different forms of PAH. 
Clinical Implications 
Endothelial dysfunction is a hallmark of pulmonary hypertension and 
congenital heart disease and recent evidence suggests that bone marrow-
derived cells participate in postnatal blood vessel repair and 
neovascularisation (206). The relative deficiency of circulating EPCs in PAH 
patients may contribute to the pulmonary vascular pathology and exercise 
intolerance in this cohort of patients. Chronic pharmacological augmentation 
with PDE5 inhibitors could offer a novel therapeutic strategy. On the other 
hand, resistance to apoptosis and proliferation of pulmonary vascular 
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endothelial cells are implicated in the progression of PAH(215) and 
incorporation of circulating progenitors may have adverse long-term 
consequences. Further studies are needed to understand the therapeutic 
implications of chronic PDE5 inhibition on circulating EPCs in PAH. 
5.7. Limitations 
One of the limitations of this study is that it did not investigate the dynamics 
of circulating EPCs and so cannot report on whether differences reflect 
alterations in EPC mobilization, survival or tissue uptake. This study provides 
no information on changes in EPCs with time in individual patients, 
particularly in relation to clinical status, measures of vascular endothelial 
function and the abundance of EPCs in the pulmonary vasculature. 
5.8. Conclusion 
Circulating EPCs are reduced in patients with Eisenmenger syndrome or 
I PAH. Circulating EPC numbers correlated with levels of inflammatory 
mediators, indices of NO synthesis and ADIVIA production and are related to 
exercise capacity and central haemodynamic markers. Treatment with 
sildenafil is associated with a dose-related increase in EPC numbers and 
may represent a novel pharmacological means of increasing circulating 
EPCs in PAH patients. 
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Chapter VI Conclusions 
6.1. Conclusion 
Adult congenital heart disease (ACHD) patients represent a heterogeneous 
patient population. Approximately one third of ACHD patient complain of 
symptoms of exercise intolerance and different mechanisms limit exercise 
capacity in different patients (7,19). To complicate things further, every 
element of the cardio-respiratory chain can limit exercise capacity in ACHD 
patients (see Figure 6.1) and it is not uncommon to have exercise limitation 
due to a combination of pathophysiologic factors in ACHD patients. Despite 
the heterogeneity, however, important similarities exist in the 
pathophysiology of exercise intolerance between different diagnostic groups 
and there are parallels to exercise limitation in patients with acquired heart 
failure. The aim of the present thesis was to investigate the mechanisms 
limiting exercise capacity in ACHD patients. Due to obvious limitations in 
time and resources the thesis had to focus on certain mechanisms of 
exercise capacity. Therefore, this thesis was focused on heart rate response 
to exercise (Chapter 2), pulmonary vascular disease (Chapter 3), cyanosis 
and shunt-lesions (Chapter 4) as well as the role of endothelial progenitor 
cells and factors affecting endothelial function such as immune inflammation 
and nitric oxide bioavailability (Chapter 5). Employing a combination of 
retrospective and prospective analyses this thesis emphasises the 
importance of an adequate heart rate increase with exercise for normal 
exercise capacity. However, it also shows that inadequate heart rate 
increase with exercise (chronotropic incompetence) is not causally related to 
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exercise intolerance in many ACHD patients and that artificially augmenting 
heart rate during exercise does not improve objective exercise capacity in 
the majority of patients with a systemic right ventricle and a pre-existing 
pacemaker. The results of this thesis rather indicate that higher heart rates 
may be detrimental in these patients by impairing diastolic filling and possibly 
myocardial perfusion at higher heart rates. Beyond the impact on exercise 
capacity chronotropic incompetence emerged as an important prognostic 
marker across the spectrum of ACHD. The results of this thesis also highlight 
the prevalence of exercise intolerance in ACHD patients with pulmonary 
arterial hypertension and cyanosis (Eisenmenger syndrome) and show that 
treatment with a pulmonary vasodilator (Bosentan) improves objective 
exercise capacity in this cohort. It also highlights the importance of adequate 
haemoglobin concentration (secondary erythrocytosis) and avoidance of iron 
deficiency in this patient population. Employing mathematical modelling this 
thesis shows how "unphysiologic" circulatory conditions (e.g. in patients with 
a bidirection cavopulmonary anastomosis) and right-to-left shunt lesions limit 
exercise capacity. It also emphasises the limitations of physiologic concepts 
such as the concept of arterial oxygen delivery in ACHD patients with 
complex conditions. Previous studies have underscored the importance of 
endothelial function for normal exercise capacity. Endothelial dysfunction is 
common in various cardiovascular cohorts including ACHD patients (59,60). 
Recent studies have highlighted the central role of endothelial progenitor 
cells in maintaining endothelial homeostasis. This study shows that patients 
with Eisenmenger syndrome - exhibiting severe exercise limitation as a 
group - have significantly lower EPC numbers and impaired EPC function 
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and that the number of EPCs correlates directly with symptoms and objective 
exercise capacity. In addition abnormal levels of immune inflammatory 
markers as well as asymmetric dimethylarginine - an inhibitor of nitric oxide 
synthesis - known to adversely affect EPC numbers and endothelial function 
were found in this patient population. Further studies are required for 
example to assess the impact of stroke volume limitations on exercise 
capacity and to investigate changes in skeletal muscle fibre composition in 
patients with ACHD. A better understanding of the mechanisms responsible 
for exercise intolerance in ACHD patients could facilitate development of 
novel therapeutic approaches or provide justification to use available 
treatment options developed for unrelated conditions in ACHD patients. 
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6,2. Figures 
Ventricular dysfunction 
Pulmonary hypertension (Chapter 3) 
Valve disease 
yOj = HR X SV x(CoO2-CvO2} 
Chronotropic incompetence {Chapter 2) 
Antiarrhythmic medication 
Conduction disease (e.g. Sinus node dysfunction) 
Implanted Cardiac Pacemaker 
Endothelial function (Chapter 5) 
Skletal muscles 
•Fiber type 
•Mitochondrial function 
Pulmonale dysfunction 
Shunt lesions / Cyanosis (Chapter 4) 
Haemoglobin concentration (Chapter 3) 
VO2 = oxygen uptake; HR = heart rate; SV = stroke volume; CaOa = arterial oxygen content; 
CvOz = venous oxygen content. 
Figure 6.1: Summary slide illustrating the mechanisms limiting exercise 
capacity in adult patients with congenital heart disease. The mechanisms 
investigated in the current thesis are printed in bold. 
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